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6ABSTRACT
Nicotine, the psychoactive component of tobacco, acts in the brain via nicotinic ace-
tylcholine receptors (nAChRs). Nicotinic receptors are ligand-gated ion channels composed of
different subunits forming either homo- or heteromeric receptors. The common property for
nAChRs is that the ion channel desensitizes during exposure to an agonist. Desensitization is
a process where repeated or prolonged exposure of a receptor to an agonist leads to a
reduction in the magnitude of response to a subsequent exposure to an agonist. The rate of
desensitization and recovery from it depends mostly on the subunit composition of the ion
channel. Chronic nicotine exposure inactivates some brain nAChRs for a longer time period.
These long-lived inactive receptor states are likely to underly the development of tolerance to
nicotine. They may also be responsible for attenuating the behavioural and physiological
effects of the drug and, therefore, be implicated in the process of nicotine dependence.
The present study was conducted in order to examine the effect of sustained chronic
nicotine administration and withdrawal on nicotine-induced striatal and limbic dopamine me-
tabolism in the rodent brain. The presynaptic effects of nicotine were studied by the determi-
nation of concentrations of dopamine and its metabolites. Further, the expression of Fos pro-
tein was investigated in rat brain to reveal the postsynaptic effects of acute and chronic nico-
tine administration and nicotine withdrawal. The main brain areas studied were the dopami-
nergic target areas, the stress-related hypothalamic areas, visual areas as well as interpedun-
cular nucleus which is rich in nAChRs. These brain areas most probably contribute to
nicotine’s dependence-producing effects.
Nicotine was administered to rats s.c. via osmotic minipumps and to mice via s.c. im-
planted nicotine-releasing reservoirs for 7 days. The effects of chronic nicotine administration
and withdrawal on nicotine-induced striatal and limbic dopamine metabolism were analysed
in post mortem brain samples of rats and mice by HPLC-EC. Nicotine-induced hypothermia
was studied in mice. Further, the Fos protein immunostaining was studied in the rat brain sec-
tions after administration and withdrawal of nicotine.
In both rats and mice the effects of acute nicotine on striatal dopamine metabolism
were attenuated during constant nicotine administration suggesting that the nAChRs regu-
lating the dopaminergic neurons were desensitized. In rat studies we found that the nAChRs
in the striatal areas appeared to be more easily desensitized than those in the limbic areas.
Interestingly, similar desensitization phenomenon was also demonstrated in nicotine’s post-
synaptic effects as measured by Fos protein expression in striatal brain areas whereas in lim-
bic areas the desensitization of the Fos protein response was not induced as easily or not at all.
In the hypothalamic brain areas the attenuation of nicotine-induced Fos expression during
constant nicotine infusion was also observed. Furthermore, evidence for a long-lasting inacti-
vation of nAChRs mediating nicotine’s effects on limbic dopamine metabolism and on Fos
expression in striatal and limbic areas in vivo was found. This indicates the development of
tolerance to these effects of nicotine. In mice, the responses of striatal DA metabolism and
body temperature to acute nicotine were both reduced during constant nicotine infusion, al-
though the differences in the time courses and the dose-relationships of these effects suggest
that they are separate phenomena. The tolerance to nicotine’s hypothermic effect could be
overcome by increasing the dose of nicotine, suggesting that tolerance, in the classical sense,
develops in the nAChRs involved in thermoregulation during chronic nicotine treatment.
In these studies the desensitization and long-lasting inactivation of nAChRs were
demonstrated in vivo in rodent brain during chronic nicotine administration and its with-
drawal. Further, the levels of desensitization and long-lasting inactivation of nAChRs in vari-
ous brain areas seemed to differ. Also, the nAChRs mediating nicotine’s effects on body tem-
perature and dopamine metabolism differ. Thus, there seems to be variations in the functional
states and/or in the subunit combinations of nAChRs mediating nicotine’s effects in brain.
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91 INTRODUCTION
Nicotine, acting at neuronal nicotinic acetylcholine receptors (nAChRs), is the primary
component of tobacco that drives its habitual use (Benowitz 1996). Smoking a
cigarette results in a rapid bolus of nicotine that activates the mesolimbic
dopaminergic system in particular, producing pleasure and reward. Further, in
smokers, nicotine levels accumulate over 6-8 h during smoking (Benowitz 1996) to
reach a low steady state concentration which has been suggested to cause both
reversible desensitization and long-term inactivation of nAChRs. In smokers the
increases in the amounts of some nAChR subtypes has been demonstrated.
Additionally, smokers seem to adjust their nicotine intake to regulate their nAChR
response (Collins and Marks 1996; Dani and Heinemann 1996; Wonnacott et al.
1996).
Nicotine and nicotinic drugs could be important in some neurological diseases because
it has been shown that a substantial decrease in nAChRs is characteristic of both
Alzheimer’s and Parkinson’s diseases (Lange et al. 1993; Whitehouse et al. 1988).
Epidemiological studies also indicate that smoking may have a protective association
in Parkinson’s disease and, to a lesser extent, Alzheimer’s disease (Morens et al.
1995). In Parkinson’s disease, there is a reduction of dopamine due to the degeneration
of the substantia nigra. It is known that presynaptic nAChRs can modulate the release
of striatal and limbic dopamine (Wonnacott 1997) and that nicotine can be
neuroprotective against glutamate-induced excitotoxicity (Akaike et al. 1994). Thus,
nicotine might be protective against Parkinson’s disease and nicotinic drugs might be
useful in therapy of Parkinson’s disease. The effects of nicotine on several other
diseases suggest that nAChRs may be involved to some extent in their pathology
and/or therapy. For example, nicotine potentiates the therapeutic properties of
neuroleptics in treating Tourette’s syndrome (Sanberg et al. 1997). It has also been
reported that the a7 subunit of nAChRs may be responsible for the attentional deficit
that may be a predisposing genetic factor for schizophrenia (Adler et al. 1998). It has
been found that a7 nAChRs are reduced in brains of schizophrenic patients (Guan et
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al. 1999). Further, it has been observed that schizophrenic patients smoke heavily to
self-medicate with nicotine (Dalack et al. 1998).
Along with activation of nAChRs by the rapid bolus of nicotine, long-term application
of the drug can lead to inactive states of these nAChRs, some of which are readily
reversible and others which are not (Collins and Marks 1996; Dani and Heinemann
1996; Hsu et al. 1996; Lester and Dani 1994; Lukas et al. 1996). An understanding of
the effects of chronic nicotine exposure on various nAChR subtypes, on
neurotransmitter release, especially dopamine, and on postsynaptic target areas might
provide better insights into mechanisms of nicotine dependence, tolerance and
withdrawal and into the effects of medication with nicotine or nicotinic drugs.
In this study the effects of constant chronic nicotine infusion and its withdrawal on
nicotine-induced striatal and limbic dopamine metabolism were investigated. The
presynaptic effects of nicotine were studied by determination of cerebral
concentrations of dopamine and its metabolites. Moreover, the expression of Fos
protein was investigated to reveal the postsynaptic effects of acute and chronic
nicotine and the withdrawal. The main brain areas studied were the dopaminergic
target areas. Additionally areas rich in nAChRs were examined, such as the stress-
related hypothalamic areas, visual areas and interpeduncular nucleus. These brain
areas are in all probability involved in the dependence producing effects of nicotine as
well as in its beneficial effects in Parkinson’s disease and schizophrenia, and also in its
ability to relieve anxiety.
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2 REVIEW OF THE LITERATURE
2.1 Neuronal nicotinic acetylcholine receptors (nAChRs)
2.1.1 nAChR subunits and their distribution
Genes that are similar in sequence to the genes encoding the subunits of nicotinic
acetylcholine receptors (nAChRs) at the neuromuscular junction encode the subunits
of neuronal nAChRs. To date, eight neuronal nAChR a genes (a2 - a9) and three
nAChR b genes (b2 - b4) have been cloned (Deneris et al. 1989b; Duvoisin et al.
1989; Elgoyhen et al. 1994; Lamar et al. 1990; Schoepfer et al. 1990; Séguéla et al.
1993; Wada et al. 1990b; 1989). Neuronal nAChR a genes encode the ligand binding
subunit with the b subunits appearing to regulate the rate at which agonists and
antagonists dissociate from the receptors, as well as contributing to the rate at which
agonist-bound receptors open. The b subunits do not function on their own, suggesting
that they form part of a hetero-oligomer receptor (Boyd 1997; Luetje and Patrick
1991). Homo-oligomeric receptors can be assembled from a7, a8 or a9 subunits, with
a7 and a8 also combining to form hetero-oligomeric receptors (Boyd 1997).
Neuronal nAChRs can be divided on the basis of snake venom toxin a-bungarotoxin
(aBgt) -binding to those receptors that do not bind aBgt and those that do bind aBgt
(Lindstrom et al. 1995). Neuronal nAChRs that do not bind aBgt include
combinations of a2, a3, a4 and a6 with b2 and b4 subunits; sometimes additionally
including a5 or b3 subunits. a4b2 nAChRs account for > 90% of the high affinity
nicotine-binding sites in rat brain (Flores et al. 1992). a3 or a6 containing nAChRs are
thought to be present in smaller amounts in more limited regions of the brain (Le
Novère et al. 1996). Another snake venom toxin distinct from aBgt is neuronal
bungarotoxin (nBgT), which has a selectivity for neuronal vs. muscle nAChRs. There
seems to be considerable parallelism between nBgT-binding sites and a3 subunit
mRNA in rodent brain (Luetje et al. 1990; Schulz et al. 1991). As a result this receptor
population is sometimes recognised as a third neuronal nAChR subclass (Decker et al.
1995).
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Neuronal nAChRs that bind aBgt include a7, a8, a9 subunits, which can function as
homomeric nAChRs. The characteristics of the homomeric subtypes include a very
rapid rate of desensitization and a high level of permeability to calcium resembling
that of the NMDA type of glutamate receptor (Bertrand et al. 1993; McGehee and
Role 1995; Revah et al. 1991; Séguéla et al. 1993). Rapid desensitization limits the
ability of homomeric nAChRs to respond to sustained intense stimulation. High
calcium permeability permits calcium ions to act as second messengers to affect many
cellular processes (Lindstrom 1997). In the brain a7 nAChRs represent > 90% of the
high-affinity aBgt binding sites, and they are present in brain at about equal amounts
with a4b2 nAChRs in a similarly wide ranging and overlapping but distinct
distribution (Séguéla et al. 1993). a8 has been found only in chickens (Schoepfer et al.
1990) and a9 is found only in limited areas of the rat nervous system (Elgoyhen et al.
1994).
Several nAChR ligands have been used to study the distribution of nAChRs, including
3H-acetylcholine (ACh), 3H-nicotine and 125I-aBgt (Clarke et al. 1985b; Marks et al.
1986). The distribution of labeling seen with 3H-ACh coincides well with 3H-nicotine
(Martino-Barrows and Kellar 1987). Table 2.1. shows the distribution of nicotinic
receptor binding of the aforementioned ligands and subunit mRNA in the rat brain.
More recently, 3H-cytisine and 3H-epibatidine have also been used to localize
nAChRs. Distribution of 3H-cytisine binding is generally consistent with that of 3H-
nicotine (Pabreza et al. 1991). Epibatidine can detect nAChRs also labeled with 3H-
nicotine or 3H-ACh. In addition, epibatidine also detects nAChRs with lower affinity
for nicotine, which are not readily detected using 3H-ACh or 3H-nicotine (Marks et al.
1998; Perry and Kellar 1995; Zoli et al. 1998).
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Table 2.1 Distribution of nicotinic receptor binding and subunit mRNA in several rat
brain regions (modified from Shacka and Robinson 1996).
Brain region* Subunit mRNA 3H-NIC and
3H-ACh binding
aBgt-binding
Cerebral cortex a3, a4, a5, a7,
b2, b4
+ +
Septum a4, a7, b2 - +
Hypothalamus a3, a4, a7, b2, b4 - +
Thalamus a3, a4, a7,
b2, b3, b4
+ -
Hippocampal
formation
a2, a3, a4, a5, a7,
b2, b4
+ +
Medial habenula a3, a4, a7,
b2, b3, b4
+ -
Amygdala a3, a4, a7, b2 - +
Substantia nigra
and/or VTA
a3, a4, a5, b2, b3 + -
Interpeduncular
nucleus
a2, a4, a5, a7,
b2, b4
+ +
Superior
colliculus
a4, a7, b2 + +
*Only areas exhibiting moderate to strong intensity of hybridization signal or ligand
binding (+) are included. Expression of multiple mRNAs in a structure does not imply
identity of receptor site within that structure. Also, distribution of receptor ligand
binding or mRNA expression is not restricted to structures listed above. – indicates not
detected.
As shown in Table 2.1, nAChRs are widely distributed in the brain. There is
abundance of evidence that neurons located in many sites of the brain express
nAChRs, which can be activated by exogenous acetylcholine and nicotinic agonists
(Clarke 1993). There is also a rich literature describing the anatomical organization of
brain cholinergic neurons (see for review Butcher 1995). In contrast, there are very
few documented sites of nicotinic cholinergic transmission in the brain. Anatomical
mapping studies show that nAChRs are present in brain areas that receive cholinergic
innervation, as shown by choline acetyltransferase (ChAT) immunoreactivity
(Armstrong et al. 1983; Wada et al. 1990b; 1989). This apparent match is consistent
with the possibility of nicotinic cholinergic transmission, but according to Clarke
(1993) it provides no more than weak evidence. At peripheral sites (e.g. autonomic
ganglia, neuromuscular junction), selective stimulation of cholinergic nerves is
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possible, while in the brain, this is difficult or impossible (Clarke 1993). Despite this,
cholinergic transmission mediated by nAChRs has been identified in cerebral cortex,
medial habenula, interpeduncular nucleus and in substantia nigra/ventral tegmental
area (Clarke 1993). Of these, the interpeduncular nucleus (IPN) is the most
convincingly identified site. In addition to the different nAChR subunits, IPN contains
amongst the brain nuclei the highest level of ChAT, acetylcholine esterase and high
affinity choline uptake activity. ChAT-like immunoreactive fibres and synaptic
boutons have also been observed in IPN (Clarke 1993).
2.1.2 Presynaptic nAChRs
Neuronal nAChRs can be categorised based on their location in the neuron. Although
this kind of classification is not clear-cut, nAChRs have mainly been divided into pre-
and postsynaptic receptors (Colquhoun and Patrick 1997). Recently, neuronal nAChRs
were subdivided even further into somatodendritic, preterminal and presynaptic
receptors (Wonnacott 1997). Preterminal receptors are axonal receptors modulating
transmitter release which is sensitive to tetrodotoxin (TTX), while in contrast,
presynaptic nAChRs elicit neurotransmitter release through a TTX-insensitive manner.
In the case of nAChRs, most receptors studied seem to have a presynaptic function in
the CNS, which does not preclude a postsynaptic role. There are undoubtedly
postsynaptic nAChRs on neurons in many areas of the brain (Colquhoun and Patrick
1997), but it is unclear whether the postsynaptic nAChRs mediating responses to
exogenously applied agonists are involved in synaptic transmission (Sorenson et al.
1998).
Activation of neuronal nAChRs on innervating axons can alter the release of a number
of neurotransmitters. It is now known that presynaptic nAChRs are present in the
nigrostriatal dopaminergic pathway and in the hippocampus. Most of the evidence in
support of a presynaptic location for nAChRs is based on lesion studies. Lesioning of
specific inputs to a nucleus leads to a loss of nicotinic-binding sites in that nucleus.
This implies that the binding sites are on the innervating axons and their loss is due to
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degeneration of these innervating axons (Colquhoun and Patrick 1997). In many cases,
however, it is difficult to rule out that the receptors are postsynaptic and their
maintenance requires the presence of the innervating axons. This is unlikely to be the
case in the striatum, where lesioning of nigrostriatal neurons with 6-hydroxy-
dopamine caused a significant decrease in the number of 3H-acetylcholine binding
sites (Schwartz et al. 1984). Because striatal neurons do not express nicotinic genes at
detectable levels (Deneris et al. 1989a; Séguéla et al. 1993; Wada et al. 1990b; Wada
et al. 1989), it is unlikely that the decrease in nicotine-binding sites is due to the loss of
receptors on these striatal neurons. The disappearance is more likely due to the loss of
presynaptic nAChRs on innervating nigral axons. These lesioning studies are
consistent with the idea that activation of nAChRs on nigrostriatal neurons modulates
transmitter release (Colquhoun and Patrick 1997). In striatal slices and synaptosomes
acetylcholine, nicotine or nicotinic agonists release dopamine in a dose- and calcium-
dependent manner (Giorguieff et al. 1977; Giorguieff-Chesselet et al. 1979; Grady et
al. 1992; Rapier et al. 1988; 1990; Soliakov et al. 1995). These nAChRs that are
activated by nicotinic agonists are likely to locate to the innervating nigral axons and
are, thus, termed “presynaptic nAChRs” (Wonnacott 1997). Distinct subtypes of
presynaptic receptors have also been shown to regulate the release of other
neurotransmitters, such as noradrenaline from hippocampus (Clarke and Reuben 1996;
Sacaan et al. 1995), glutamate from prefrontal cortex, medial habenula and
hippocampus (Gray et al. 1996; McGehee et al. 1995; McGehee and Role 1995; Vidal
and Changeux 1993), GABA from the interpeduncular nucleus (Léna et al. 1993) and
hippocampus (Alkondon et al. 1997), acetylcholine from cortex and hippocampus
(Lapchak et al. 1989; Rowell and Winkler 1984) and 5-hydroxytryptamine from
striatum (Reuben and Clarke 2000).
2.1.3 Pharmacology of brain nAChRs
Nicotinic receptors in central nervous system, ganglions and at the neuromuscular
junction differ in their affinity and response to various cholinergic agonists and
antagonists. Each receptor subtype has a specific pattern of sensitivity to the agonists
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acetylcholine, nicotine, DMPP or cytisine (see Table 2.2). Both a and b subunits
contribute to the pharmacological properties of each subtype (Luetje and Patrick
1991).
Table 2.2 Sensitivity of rat nAChRs expressed in oocytes to various agonists
(modified from Boyd 1997).
Subtype
combination
Agonists relative
potency
References
a2b2 N > D = A > C Luetje and Patrick 1991
a3b2 D > A > N >C Cachelin and Jaggi 1991,
Luetje and Patrick 1991
a4b2 A = N > D > C Luetje and Patrick 1991
a2b4 C >N > A > D Luetje and Patrick 1991
a3b4 C > N = A = D Cachelin and Jaggi 1991,
Luetje and Patrick 1991
a4b4 C > N > A > D Luetje and Patrick 1991
a7 N = C > D > A Séguéla et al. 1993
a9 A >> D Elgoyhen et al. 1994
Note: N = nicotine; A = acetylcholine; C = cytisine; D = 1,1-dimethyl-4-
phenylpiperazinum.
2.1.4 Desensitization of neuronal nAChRs
Desensitization is a process where repeated or prolonged exposure of a receptor to an
agonist leads to a reduction in the magnitude of response to subsequent exposure to the
agonist. The desensitization of the nAChR response is an intrinsic property of the
isolated nAChR protein which does not require any obligatory covalent modification
(Changeux et al. 1987). In 1957, Katz and Thesleff reported that when acetylcholine
was applied iontophoretically to frog skeletal muscle, the tissue showed a typical
response; but when the agonist was allowed to act for a prolonged time, the tissue no
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longer responded. A cyclical model of desensitization was then suggested for nAChRs
(Katz and Thesleff 1957; Rang and Ritter 1970; Figure 2.1).
Figure 2.1  A cyclical model for desensitization (Katz and Thesleff 1957): S = conditioning
drug concentration; A = free receptors; SA = active drug-receptor complex (=open ion
channel); SB = ’refractory’ drug-receptor complex (= desensitized state), a and b = affinity
constants; k1 being the forward, k2 the reverse rate constant of the desensitizing step.
This model allows for two paths to desensitization. One route consists of the receptor
in a resting state which rapidly binds acetylcholine to form an active complex (= open
ion channel) which then slowly converts to a desensitized state (= acetylcholine still
bound but the channel is non-conducting). When acetylcholine is no longer present the
agonist dissociates from the receptor and the receptor returns to the resting state. The
conversion from the active state to the desensitized state involves a change in the
binding site for the agonist molecule from a low affinity state to a high affinity state
(Sine and Taylor 1979; Weiland and Taylor 1979). Thus, the continued presence of an
agonist molecule will eventually shift nAChR from a low affinity resting state through
an active state and then to a high affinity desensitized state. A second route to the
liganded desensitized form of the receptor can occur at low agonist concentrations at
which binding to the unliganded, desensitized form of the receptor occurs. In other
words, nAChRs can be desensitized by activating and subactivating concentrations of
agonists (Fenster et al. 1997; Grady et al. 1994; 1997; Lester and Dani 1995; Marks et
al. 1994; 1996). Both routes to desensitization are possible due to the desensitized
conformation of the receptor having a higher affinity for the agonist than the resting
receptor and that the unliganded resting state and desensitized state of the receptor are
interconvertible (Katz and Thesleff 1957; Marks 1998). Thus, following exposure to
either activating or subactivating concentrations of agonist for sufficient time, a
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significant population of receptors are refractory to activation because of the
accumulation of the liganded desensitized nonfunctional receptor.
Most of the experimental data dealing with various aspects of nAChR desensitization
can be accounted for by the general model (Changeux et al. 1984; Heidmann et al.
1983; Neubig and Cohen 1980) which is a modified version of the cyclic model
proposed by Katz and Thesleff. Formally, this model is within the general framework
of the concerted model for allosteric transitions in multimeric proteins (Monod et al.
1965) as applied to the nAChR (Karlin 1967). This general model consists of four
states for the nAChR molecule: (1) resting (closed) or (2) active (open) state or (3)
slowly or (4) rapidly desensitized, refractory, high affinity states of the receptor
(Changeux et al. 1984; Edelstein et al. 1996). Therefore, desensitization consists of
two distinct kinetic processes, a fast and a slow component (Felzt and Trautmann
1982; Sakmann et al. 1980). After brief desensitization, most receptors only have time
to reach a fast desensitized state from which recovery is rapid. During prolonged
desensitization, more receptors are converted to the slowly reached desensitizated
state, from which recovery is slow (Fenster et al. 1999a). In addition, it has been noted
that prolonged exposure to acetylcholine causes an incomplete recovery of receptor
function which could be termed as long-lasting inactivation and which may represent
yet another phase of desensitization (Simasko et al. 1986) or more likely, a mechanism
that can be distinguished from reversible nAChR desensitization (Ke et al. 1998;
Rowell and Duggan 1998).
There are different factors which appear to influence the desensitization of neuronal
nAChRs. The intracellular domains of transmembrane receptors, including muscle-
type nAChRs, are readily phosphorylated by various intracellular kinases, which have
been shown to both promote desensitization and increase the rate of it (Huganir et al.
1986; Huganir and Miles 1989). However, Cachelin and Colquhoun (1989) cast doubt
to the idea that phosphorylation could be a normal mechanism to produce
desensitization, because the process was observed either in reconstituted receptor or in
artificial intracellular medium which contains no ATP. Later, it has been shown that in
the case of neuronal nAChRs, their phosphorylation state appeared important in
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determining recovery from desensitization (Fenster et al. 1999a; Khiroug et al. 1998).
Furthermore, when nAChRs are desensitized, they become susceptible to modulation
by calcium, via intracellular second messenger mechanisms such as serine/threonine
kinases and calcineurin (Khiroug et al. 1998).
For heteromeric nAChRs the a subunit determines the apparent affinity of nicotine to
the active and desensitized states of a nAChR; the b subunit contributes by
determining the overall time course of the development of desensitization (Cachelin
and Jaggi 1991; Fenster et al. 1997). Generally it has been found that desensitization
develops rapidly in b2-containing nAChRs and slowly in b4-containing nAChRs; a4-
containing receptors seem to be more sensitive to desensitizing levels of nicotine than
a3-containing receptors (Fenster et al. 1997; Vibat et al. 1995). The homomeric a7
receptor has the highest sensitivity to nicotine as regards both activation and
desensitization; a7 nAChRs also demonstrate the fastest desensitization kinetics
(Couturier et al. 1990; Fenster et al. 1997; Revah et al. 1991; Séguéla et al. 1993). The
desensitization of homomeric a7 receptors suggests that the b subunit plays a
modulatory, rather than a permissive role, in desensitization (Fenster et al. 1997).
The process of desensitization has recently attracted increasing attention because of its
ability to influence synaptic transmission over extended periods, thus controlling the
time course of synaptic events and enabling sustained changes in the efficacy of
synaptic transmission (Jones and Westbrook 1996). Also, desensitization has been
suggested to play a role in nicotine dependence in smokers (Lukas et al. 1996; Marks
1998). Desensitization of nAChRs on prolonged exposure to nicotine has been
implicated in cognitive enhancement, relief of depression and anxiolysis but also in
withdrawal and substance dependence in smokers (Lindstrom 1997; Lukas et al.
1996). Many smokers report that the first cigarette of the day is the most pleasurable
(Benowitz 1996; Dani and Heinemann 1996) and so the effect of subsequent cigarettes
may depend on the interplay between activation and desensitization of multiple
nAChRs (Pidoplichko et al. 1997). Pidoplichko et al. (1997) noted that even the low
concentration of nicotine (0.1 mM) applied in vitro, which may be maintained during
much of a smoker’s day (usually 0.1-0.5 mM), can cause significant desensitization of
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nAChRs. The rate and recovery from desensitization varies depending on which types
of nAChRs are expressed on a particular neuron or in different areas of the brain.
Thus, multiple phases of nAChR desensitization and recovery could underlie aspects
of tolerance such that a second dose of nicotine does not elicit the same effects as the
first. The sustained stay of nicotine in the circulation and slow recovery from deep
levels of desensitization may explain the pleasurable effect of the first cigarette of the
day. This could be explained by the hypothesis that nAChRs only completely recover
from long-term desensitization after a night-time abstinence from smoking
(Pidoplichko et al. 1997).
2.1.5 Upregulation of nAChRs
Usually, chronic agonist treatment results in a decrease, or downregulation of receptor
number, which is accompanied by tolerance to the agonistic actions of the drug in
question. Further, chronic antagonist treatment seems to elicit an upregulation of
receptor number and an accompanying supersensitivity to agonist actions.
Surprisingly, chronic nicotine exposure increases the amount of brain high affinity 3H-
ACh or 3H-nicotine binding sites (primarily a4b2 nAChRs) (Flores et al. 1992; Marks
et al. 1983; 1985; Marks and Collins 1985; Schwartz and Kellar 1983; 1985) while
producing a smaller increase in the amount of aBgt binding sites (a7 nAChRs)
(Collins and Marks 1987; Marks et al. 1983) in both rats and mice. Nicotine and
acetylcholine bind to the same sites in mouse and rat brain whereas aBgt binding
shows different distribution (Clarke et al. 1985b; Marks et al. 1986). The increase of
high-affinity binding sites is not because of an increase in transcription of a4 and b2
subunits (Marks et al. 1992). Instead, it may be the result of a decrease in the rate of
turnover of a4b2 nAChRs on the cell surface (Peng et al. 1994). Rowell and
Wonnacott (1990) found a strong correlation between the Bmax of nicotine-binding and
the nicotine-stimulated release of dopamine in the same tissue, indicating that the
increased binding sites are functional receptors. Contrary to this, Marks et al. (1993)
observed reduced nicotinic receptor function after chronic nicotine infusion at doses
which result in upregulation of nicotinic receptors. Therefore, upregulation is thought
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to result from a nicotine-induced conformational change, perhaps to a desensitized or
inactivated conformation (Marks et al. 1983; Schwartz and Kellar 1983) rather than a
result of signals mediated by ion flow through the a4b2 nAChR channel. The former
suggestion is probably the case because the nicotinic antagonist mecamylamine can
also induce upregulation of both cloned a4b2 nAChRs and brain nAChRs (Collins et
al. 1994; Pauly et al. 1996; Peng et al. 1994). The mechanisms of upregulation of a3
and a7 nAChRs appear to differ from those of a4b2 nAChRs not only in nicotine
sensitivity, extent and surface expression, but also pharmacologically, in that
mecamylamine was unable to induce upregulation of a3 and a7 subunits (Peng et al.
1997). Differences in regulation among nAChRs could be explained by subtype-
specific nicotine sensitivities of both the desensitized and active receptor states
(Fenster et al. 1997).
Later, conflicting results have been obtained when the correlation of receptor
desensitization and upregulation have been thoroughly studied in vitro. Fenster et al.
(1999c) demonstrated that the nicotine concentration required to induce both
desensitization and upregulation is the same, while some others (Peng et al. 1994;
Whiteaker et al. 1998) have shown that the concentrations necessary to induce
desensitization and upregulation can differ by several orders of magnitude, specifically
that upregulation needs a greater nicotine concentration than desensitization. This
discrepancy may be explained by differences in methodological details; whether cell
homogenates (Whiteaker et al. 1998) or intact oocytes (Fenster et al. 1999c) have been
utilised and whether the nAChRs studied were expressed on the surface or
intracellularly. Clearly, some form of interaction of nAChRs with nicotine is likely to
precipitate both desensitization and upregulation, meaning that there might be some
common steps in the mechanisms of both processes (Ke et al. 1998).
The possible relevance of the nicotine-induced changes in receptor numbers was
emphasized by the findings that nicotinic receptors labeled by 3H-nicotine, 3H-
epibatidine and 3H-cytisine are increased in homogenates of autopsied brain samples
from smokers (Benwell et al. 1988; Breese et al. 1997; Perry et al. 1999). The increase
in 3H-nicotine binding levels in humans was dose-dependent and mostly affected by
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the daily nicotine intake before death, rather than the overall amount smoked during a
lifetime (Breese et al. 1997). Smokers who had quit smoking at least 2 months before
death had levels of 3H-nicotine binding which were comparable to levels found in non-
smoking subjects (Breese et al. 1997). This suggests that nicotine-induced up-
regulation of receptor numbers is a temporary effect, similar to that found in rodents
(Collins et al. 1990a; Marks et al. 1985). The study of Breese et al. (1997) along with
studies in rodents clearly implies that the increased nicotinic receptor numbers in
smokers’ brains are a consequence of smoking, rather than smoking behaviour being a
consequence of an intrisincally higher number of nicotinic receptors (Perry et al.
1999).
2.1.6 Nicotine-induced development of tolerance
Drug tolerance is a state of decreased responsiveness to the pharmacological effect of
a drug as a result of prior exposure to that drug or to a related drug. The degree of
tolerance, in general, may vary within very wide limits. Usually in the tolerant
organism, although the ordinarily effective dose is less effective or is even entirely
ineffective, an increased dosage will again elicit the typical drug response. Thus, as a
rule, tolerance is a quantitative change in sensitivity to a drug. Sometimes, however,
the drug effect cannot be obtained at any dosage in the tolerant organism (Cox 1990).
Chronic nicotine exposure renders some brain nAChRs inactivated for a long time
period (see section 2.1.4). These long-lived inactive receptor states are likely to
underlie the development of tolerance to nicotine (Fenster et al. 1999b) and may be
responsible for attenuation of the behavioural and physiological effects of nicotine
such as locomotor depressant actions (Marks et al. 1983; Marks and Collins 1985;
Stolerman et al. 1973) and decrease in body temperature (Collins et al. 1988b;
Mansner et al. 1974; Marks et al. 1983; Marks and Collins 1985).
Early studies performed in mice suggested that the upregulation of brain nicotinic
receptors might be associated with tolerance to nicotine (Marks et al. 1983; 1985)
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whereas later studies indicate that upregulation can occur before tolerance
development (Marks et al. 1991) and tolerance can develop without receptor changes
(Pauly et al. 1992). Similarly, studies with the rat have shown that tolerance to
nicotine’s locomotor depressant effects is not necessarily associated with receptor
changes (Collins et al. 1990b). It seems that tolerance to the effects of nicotine in vivo
cannot be fully explained by either the changes in the number of binding sites or in the
functional state of the nAChRs (Marks et al. 1993).
2.2 Nicotine and dopamine
2.2.1 Dopaminergic pathways in the brain
Dopaminergic neurons can be divided into 3 major classes depending on the length of
the dopaminergic tract: ultrashort, intermediate-length and long-length systems
(Cooper et al. 1996). The long projections consist of three separate tracts: nigrostriatal,
mesolimbic and mesocortical projections (Björklund and Lindvall 1984; Figure 2.2)
Cell bodies of the neurons forming these major ascending dopaminergic pathways are
located in the brainstem, in the substantia nigra pars compacta (A9) and ventral
tegmental area (A10) (Dahlström and Fuxe 1964; Ungerstedt 1971). The A9 neurons
project mainly to the caudate-putamen or to the dorsal striatum forming the
nigrostriatal dopamine system (Fuxe et al. 1985) A minor component of the
nigrostriatal system projects from the A8 area (dopamine-rich neurons dorsal to A10
and caudal to A9) to the ventral putamen (Björklund and Lindvall 1984; Ungerstedt
1971). The mesolimbic dopaminergic pathway is formed by neurons that project from
the A10 area to the nucleus accumbens (i.e. the ventral striatum), olfactory tubercle
and other limbic regions such as amygdala, hippocampus and septum. In addition, the
A10 area sends axons to the cortical areas, e.g. to the medial, prefrontal, entorhinal and
cingulate cortex, and this system is known as the mesocortical dopaminergic pathway
(Björklund and Lindvall 1984).
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Figure 2.2. The nigrostriatal, mesolimbic and mesocortical dopaminergic projections in rat
brain. Adapted from Wiley et al. (1996), with permission. TO = the olfactory tubercle.
The nigrostriatal system is involved in the regulation of movement and also subserves
some cognitive processes whereas the mesolimbic pathway is involved in arousal,
locomotor activity, reward, motivational and affective states and euphoria induced by
drugs (Fuxe et al. 1985). Behavioural studies have shown that mesolimbic and
nigrostriatal dopaminergic systems are involved in different aspects of activation,
probably linked with incentive-motivational or reward processes (including those
engaged by drugs of abuse), in the case of the mesolimbic (ventral striatal) system, and
response preparatory mechanisms, in the case of the mesostriatal (dorsal striatal)
system (Robbins et al. 1998). These differential effects on behaviour may be explained
by the inputs to these regions. The ventral striatum receives a strong allocortical input
from the prefrontal cortex and amygdala, which may be important for the convergence
of information about reward, whereas the neocortical inputs of the dorsal striatum may
be implicated in cognitive and response-related functions, such as visuospatial
processing and attention to action (Dunnett and Robbins 1992). The activity of dorsal
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and ventral striatum may be co-ordinated as a general response to activating stimuli
which leads to behavioral activation (Dunnett and Robbins 1992). The mesocortical
pathway is important in higher cortical functions (Fuxe et al. 1985) and finally the
frontal cortical dopamine projections may have important role in the regulation of
subcortical dopamine activity (Dunnett and Robbins 1992).
2.2.2 Synthesis and metabolism of dopamine
Dopamine synthesis originates from the amino acid precursor tyrosine, which is
transported across the blood-brain barrier and is actively concentrated by
dopaminergic neurons. The hydroxylation of L-tyrosine by tyrosine hydroxylase to L-
dihydroxyphenylalanine (L-DOPA) is the rate-limiting step of dopamine synthesis. L-
DOPA is subsequently converted to dopamine by L-aromatic amino acid
decarboxylase in the cytoplasm of cells (Cooper et al. 1996). Active transporters then
carry dopamine to synaptic vesicles, where the molecules are protected from
catabolizing enzymes. Amongst other factors, presynaptic dopamine autoreceptors
modulate the rate of tyrosine hydroxylation. Autoreceptors are activated by dopamine
released from the nerve terminal, resulting in feedback inhibition of dopamine
synthesis. Autoreceptors can modulate both synthesis and release of dopamine.
Dopamine synthesis also depends on the rate of impulse flow in the dopaminergic
pathway (Cooper et al. 1996). Dopamine is released in a calcium-dependent manner
when an action potential invades the terminal of the neuron. The extent of dopamine
release appears to depend on the rate and pattern of firing (Cooper et al. 1996). The
burst-firing pattern leads to enhanced release of dopamine from dopaminergic neuron
compared with single-spike pattern (Grace and Bunney 1984a; 1984b). Most of the
released dopamine is then transported back into the terminal by specific dopamine
transporter molecules (Reith et al. 1997).
The metabolism of dopamine can take place in the synaptic cleft, in the cytoplasm of
nerve terminal and inside glial cells. The main enzymes, which metabolize dopamine,
are catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO) (Sharman
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1973). COMT is found both in membrane-bound and in cytoplasmic soluble forms
(Rivett et al. 1983). The soluble COMT is localised in glial cells and the membrane-
bound COMT in postsynaptic neurons (Kaakkola et al. 1987; Rivett et al. 1983). MAO
is located both intra- and extraneuronally (Agid et al. 1973).
Figure 2.3. A simplified diagram of the metabolism of dopamine. Abbreviations: DA =
dopamine; DOPAC = 3,4-dihydroxyphenylacetic acid; HVA = homovanillic acid; 3-MT = 3-
methoxytyramine; COMT = catechol-O-methyltransferase, MAO = monoamine oxidase.
Wood and Altar (1988), with permission.
In dopaminergic nerve terminals dopamine is metabolised intraneuronally to the
corresponding aldehyde by MAO. The aldehyde is subsequently oxidised to 3,4-
dihydroxyphenylacetic acid (DOPAC) by aldehyde dehydrogenase. After diffusing out
of the neurons DOPAC can be further metabolised to homovanillic acid (HVA) by
COMT. Dopamine, released into the synaptic cleft, can be inactivated both by
reuptake into the dopaminergic nerve terminals, and by inactivation involving COMT.
The extraneuronal dopamine metabolite, 3-methoxytyramine (3-MT) is formed from
dopamine by COMT and can be further metabolised to HVA by MAO and aldehyde
dehydrogenase (Fig. 2.3).
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DOPAC can be used as an indicator of intraneuronal synthesis and metabolism of
dopamine (Roffler-Tarlov et al. 1971) since a substantial amount of DOPAC is derived
from the newly formed pool of dopamine (Zetterström et al. 1988). HVA is formed by
both MAO and COMT, indicating the sum of dopamine synthesis, metabolism and
release (Roffler-Tarlov et al. 1971; Westerink and Spaan 1982). As HVA is
predominantly derived from O-methylation of DOPAC, the changes in the tissue and
extracellular content of HVA follow those of DOPAC in rats (Westerink 1985; Wood
and Altar 1988). In mice, however, DOPAC and HVA are not formed as consequtive
products in the same metabolic pathway, in that little DOPAC is converted to HVA in
mouse brain (Sharman 1973). Tissue contents as well as extracellular concentration of
3-MT can be used as an index of dopamine release (Kehr 1976; Wood and Altar 1988)
provided that the effects of post mortem changes have been eliminated.
2.1.6 Nicotine and brain dopaminergic systems
Nicotine appears to differentially affect dopamine release, metabolism and the
electrophysiological properties of dopaminergic neurons in nigrostriatal and
mesocorticolimbic dopaminergic systems. Nicotine enhances striatal and limbic
dopamine turnover and metabolism. Nicotine increases in vitro 3H-dopamine release
from striatal slices and synaptosomes (Arqueros et al. 1978; Grady et al. 1992; Rapier
et al. 1988; Westfall 1974) and from minced preparations of nucleus accumbens
(Rowell et al. 1987). Nicotine increases in vivo striatal DOPAC and HVA
concentrations (Freeman et al. 1987; Haikala et al. 1986; Lichtensteiger et al. 1976;
Nose and Takemoto 1974; Roth et al. 1982) and limbic, mainly accumbal, DOPAC
concentrations (Grenhoff and Svensson 1988). Nicotine has been reported to increase
the rate of disappearance of striatal and accumbal dopamine after blockade of
synthesis by a-methyl-p-tyrosine (Andersson et al. 1981b; Lichtensteiger et al. 1982).
Further, nicotine elevates the extracellular dopamine levels in both striatal (Damsma et
al. 1988; Imperato et al. 1986; Toth et al. 1992) and limbic brain areas (Benwell and
Balfour 1992; Imperato et al. 1986; Mifsud et al. 1989; Nisell et al. 1994) as measured
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by in vivo microdialysis. Systemic or local infusion of nicotine also stimulates the
firing frequency of midrain dopaminergic neurons (Calabresi et al. 1989; Clarke et al.
1985a; Grenhoff et al. 1986; Lichtensteiger et al. 1982). A dose-response comparison
between substantia nigra and VTA reveals that systemic nicotine produces a larger
increase in firing frequency of dopaminergic neurons in VTA (Mereu et al. 1987;
Westfall et al. 1989). This correlates well with the observations that acutely
administered nicotine preferentially activates limbic dopamine metabolism, turnover
and release (Andersson et al. 1981a; Brazell et al. 1990; Grenhoff and Svensson 1988;
Imperato et al. 1986).
Nicotine-induced release of DA in vitro from rat striatal slices and synaptosomes has
been reported to attenuate (Grady et al. 1994; Rowell and Hillebrand 1994; Schulz and
Zigmond 1989) during or after prolonged nicotine exposure suggesting that the
desensitization of the nAChRs is involved. It has been hypothesized that at least two
different nAChR subunit complexes are involved in nicotine-induced dopamine
release from rat striatal synaptosomes, one of which has a a3b2 subunit composition
(Kaiser et al. 1998; Kulak et al. 1997) and the other has a a4b2 subunit composition
(Sharples et al. 2000). In contrast, others (Grady et al. 1997) have suggested that both
the transient and persistent phases of nicotine-induced dopamine release from striatal
synaptosomes are mediated by only one type of receptor, which contains both a3 and
a4 as well as b2 subunits.
The effect of chronic nicotine pretreatment in vivo on nicotine-induced changes in
dopaminergic activity seems to depend on the response measured, dosing schedule and
species. During prolonged constant nicotine infusion the acute nicotine-evoked
increase of extracellular dopamine in the NAcc and in the dorsal striatum was
inhibited and the elevation of accumbal dopamine metabolites was attenuated
suggesting desensitization of the receptors mediating nicotine-induced mesolimbic and
nigrostriatal DA responses (Benwell and Balfour 1997; Benwell et al. 1995). On the
other hand, Damsma et al. (1989) and Nisell et al. (1996) reported no change in the
nicotine-induced increase of DA-release in the NAcc of rats when nicotine was given
by repeated injections. After intermittent nicotine treatment even sensitization of the
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nicotine response in the striatum, the NAcc and the prefrontal cortex has been reported
(Balfour et al. 1998; Benwell and Balfour 1992; Marshall et al. 1997; Reid et al. 1996;
Shoaib et al. 1994). In mice, nicotine-induced changes in striatal dopamine metabolism
were abolished at 24 hours after withdrawal from 7-week oral nicotine administration
suggesting the development of tolerance (Pietilä et al. 1996).
Nicotine has variable effects on locomotor activity depending on animal species, drug
dosage, route of administration and duration of treatment. Acute systemic
administration of nicotine in rats produces a biphasic effect on locomotor activity, so
that an initial depressant activity is replaced by a stimulant action (Clarke and Kumar
1983; Stolerman et al. 1973). In mice, acute nicotine usually decreases locomotor
activity (Collins et al. 1988a; Hatchell and Collins 1980) and only few authors have
reported a stimulating effect of acutely administered nicotine (Nordberg and Bergh
1985; Sparks and Pauly 1999). In rats, the locomotor stimulant effects of nicotine have
been suggested to depend upon its ability to stimulate mesolimbic dopamine release
(Benwell and Balfour 1992; Clarke 1990). However, recent studies have shown that
the relationship between the stimulatory effects of nicotine on locomotor activity and
mesolimbic dopamine is more complex than orginally thought (Balfour et al. 1998).
Tolerance towards nicotine’s depressant effect on locomotor activity has been
demonstrated in rats and in mice (Benwell et al. 1995; Clarke and Kumar 1983; Marks
et al. 1983; Pietilä et al. 1998). However, a more pronounced stimulatory effect
(reverse tolerance or behavioural sensitization) has been demonstrated in chronically
treated rats (Clarke and Kumar 1983; Ksir et al. 1985) and more recently, in mice
(Gäddnäs et al. 2000). In this mouse study, the increased locomotor activity in the
nicotine-treated mice correlated to increased striatal concentrations of DOPAC and
HVA, indicating enhanced striatal metabolism. This finding suggests that the cerebral
dopaminergic systems might be important in the mediation of the nicotine-induced
locomotor hyperactivity in mice as they have been shown to be of importance in rats
(Clarke 1990; Pietilä and Ahtee 2000).
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2.3 Nicotine and c-fos
2.3.1 Immediate-early gene c-fos
Extrinsic signals can modulate cell function in different ways. Excitation of neurons
has two general consequences. The first is the short-lived response of the cell that is
elicited immediately after application of the stimulus and which has no requirement for
ongoing protein synthesis. An example of such a response is an increase or a decrease
in the firing rate of a particular neuron. Secondly, relatively brief periods of excitation
can bring about longer-term responses that are dependent upon protein synthesis and
that involve alterations in the expression of specific genes (Curran and Morgan 1987;
Morgan and Curran 1991a).
Genes that are activated rapidly and transiently after cell stimulation and whose
expression cannot be prevented by protein synthesis inhibitors are known as the
immediate-early genes (IEGs) (Sheng and Greenberg 1990). IEGs are believed to
encode transcription factors, which will, in turn, modify the expression of other genes
known as target genes (Sheng and Greenberg 1990; Fig. 2.4). Target gene expression
can then modify the phenotype of the cell in question (Herrera and Robertson 1996).
Target genes are also involved in the processes such as learning and memory, drug
tolerance/sensitisation (Hughes and Dragunow 1995). Neurotransmitters can have
differential effects on the same target gene in different cell types or on different genes
in the same cell by inducing distinct patterns of IEG production or by causing IEGs to
undergo different post-translational modifications (Esterle and Sanders-Bush 1991).
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Figure 2.4 Proposed model for the role of cellular IEGs in stimulus-response coupling.
Extracellular ligands (L) interact with receptors (R) and activate second messenger systems
via membrane-transducing components (T). Second messengers elicit rapid alterations that
lead to short term response. The same second messengers, directly or indirectly, act to induce
transcription of the cellular IEGs (A-C). IEGs may be components or regulators of the signal
transduction cascade (e.g. receptors, G-proteins) or they may promote the transcriptional
activation of further target genes (1-7); e.g. those encoding ion channels, neuropeptide
precursors etc., that cause changes in long-term responses. Potential regulation of IEGs by
negative feedback control is indicated by dotted lines. Curran and Morgan (1987), with
permission.
The IEG that was discovered first is the well-characterized proto-oncogene c-fos
(Curran et al. 1983), which encodes a nuclear phosphoprotein (Fig. 2.5). Fos protein
undergoes extensive post-translational modification and forms a dimeric complex with
Jun, the protein encoded by c-jun. (Curran and Morgan 1987). Dimerization occurs
through an a-helical domain that is termed a leucine zipper. Fos-Jun heterodimers
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exhibit sequence-specific DNA binding to the canonical motif TGACTTCA. Several
studies have established (Curran and Franza 1988) that this DNA sequence is the
binding site for the transcription factor activator protein 1 (AP-1).
Figure 2.5  Induction of the Fos protein is elicited by extracellular stimuli such as
neurotransmitters. These agents produce signals that lead to a transcriptional activation of the
c-fos gene. mRNA accumulates transiently, the Fos protein is synthetized and transported to
the nucleus and extensively modified. In the nucleus, Fos forms a protein complex with one
of the several cellular proteins and becomes associated with chromatin Curran and Morgan
(1987), with permission.
Indeed, Fos and Jun, in addition to a number of Fos- and Jun-related proteins, are
constituents of AP-1 (Curran and Franza 1988). Thus, Fos acts in concert with other
immediate-early gene products to regulate transcription of other target genes (Morgan
and Curran 1991a).
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The intracellular mechanisms that lead to activation of c-fos gene are somewhat
unclear (Sheng and Greenberg 1990). The activation of many second messenger
pathways leads to early response gene expression and these may include stimulation of
adenylate cyclase, protein kinase C and tyrosine kinases; Ca2+ entry into cells; and
mobilisation of intracellular Ca2+. The biochemical events that couple these second
messenger systems to early response gene expression remain unknown (Sharp et al.
1993b). However, intracellular Ca2+ appears to play a central role in neuronal cells for
coupling neuronal depolarisation to c-fos expression (Sheng and Greenberg 1990).
Ca2+ entry through voltage-activated Ca2+ channels and the resultant activation of a
calmodulin-dependent protein kinase, or a similar enzyme, and phosphorylation of
CRE-binding protein (CREB), which initiates the transcription of c-fos, have been
strongly suggested as the means by which depolarization induces the c-fos gene (Sharp
et al. 1993b).
Some of the early studies suggested the use of Fos immunostaining (Fos IS) as an
indicator of neuronal activity (Dragunow and Faull 1989; Hunt et al. 1987; Sagar et al.
1988). Several more recent studies have suggested (Herrera and Robertson 1996;
Hughes and Dragunow 1995) that Fos IS provides a method to map the pattern of
postsynaptic stimulation within the intact nervous system with single cell resolution
(Morgan and Curran 1991b) since Fos-staining is localized to the cell nucleus (Sagar
et al. 1988). A potential use of Fos staining is to define the cellular targets of
neuroactive substances, like nicotine. The basal expression of Fos is relatively low in
most brain regions and Fos is expressed rapidly and transiently after a variety of
physiological and pharmacological stimuli (Sagar et al. 1988). These stimuli include,
for example, seizure activity (chemically and electrically induced), kindling, brain
injury (e.g. mechanical), sensory stimulation (noxious, visual, olfactory,
somatosensory), stress, learning, the induction of LTP and pharmacological activation
of specific receptor agonists and antagonists (Herrera and Robertson 1996; Hughes
and Dragunow 1995). Fos-IS is most informative when novel stimuli are applied or
when the animal is stimulated after a period of sensory deprivation, whereas after
prolonged stimulation it will yield negligible results (Chaudhuri 1997). Fos expression
is an anatomical technique for metabolic mapping similar in some respects to 2-
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deoxyglucose autoradiography (2-DG), which is a measure of total glucose
consumption in brain and therefore, useful for mapping regional changes of glucose
metabolism (Sharp et al. 1993b). Although lacking the quantitative potential of the 2-
DG method, Fos expression offers cellular resolution (Sharp et al. 1993b) which is not
achieved by the 2-DG method.
Mapping the functional activity in the brain with Fos or other IEG products has two
major drawbacks: limited cell-type expression and stimulus-coupling uncertainty
(Chaudhuri 1997). Only a subset of neurons may express a particular transcription
factor (e.g. Fos) and neurons in some brain structures may not express it at all (Labiner
et al. 1993). Thus, Fos cannot be considered to be a general marker of neural activity
that can be applied throughout the central nervous system (Chaudhuri 1997). A causal
link between IEG expression and a particular triggering event is often difficult to
establish, since IEG expression can be influenced by multiple receptor systems and by
different signal transduction pathways. Furthermore, with in vivo preparations it is
difficult to establish whether the pattern of Fos expression was produced by the
specific stimulus that was applied or by some non-specific feature of the experimental
condition or even by an unrelated mental or endocrine event. To verify the stimulus-
response association, control animals that are handled similarly to the experimental
animals and carefully controlled experimental conditions should be used (Chaudhuri
1997; Dragunow and Faull 1989). However, these controls can only resolve the
uncertainty at a regional level; they do not permit a positive association to be made at
the cellular level for any of the individual Fos-stained neurons (Chaudhuri 1997).
Though caution should be exerted in overinterpreting the presence or absence of Fos-
IS in a particular situation, the maps of Fos expression may still prove useful (Morgan
and Curran 1991b). A dual-activity mapping technique may provide an internal control
and thus resolve the above-mentioned problems at the cellular level. The technique
relies on the different spatial locations of transcription factor mRNA and protein
(cytosolic and nucleic, respectively) and the different temporal patterns of their
expression (Chaudhuri 1997). To date, this has only been tested succesfully with one
IEG, namely zif268 mRNA and protein in monkeys (Chaudhuri 1997) but not with c-
fos.
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2.3.2 Acute nicotine and c-fos
Acute nicotine administered using various protocols (i.p., s.c., i.v.-infusion, local
microinfusions) activates different groups of rat brain areas (see Table 2.3).
Table 2.3 Rat brain areas activated after various acute nicotine administration
protocols.
Fos/
c-fos
Nicotine dose Time Brain areas
activated
Reference
Fos 2 mg/kg/h i.v. 60 min SC, MT, IPN Ren and Sagar 1992
c-fos 1.5 mg/kg i.p. 30 min PC, CG, MH, DG, PVN,
LC
Sharp et al. 1993a
Fos 0.1 mg/kg i.v. 60 min Cg, PVN, SON, NTS-
A2, NTS-C2, LC, ACe
Matta et al. 1993
Fos 0.4 mg/kg s.c. 120 min SMN, MT, IPN, CLI, SC Pang et al. 1993
Fos 1 mg/kg s.c. 120 min Cg, PC, CPU, NAcc Kiba and Jayaraman
1994
Fos 30 mM, 300 mM
into SON
80 min SON Shen and Sun 1995
Fos 0.09-0.18 mg/kg
i.v.
60 min NTS-A2, NTS-C2, LC,
PVN
Valentine et al. 1996
Fos 8.0 mg/side into
VTA
120 min NAcc Panagis et al. 1996
Fos 0.35 mg/kg s.c. 90 min Cg, FC, PaC, OC, PC,
NAcc, CPU, MH, ACe,
ThN, SC
Mathieu-Kia et al.
1998
ACe = central nucleus of amygdala, Cg = cingulate cortex, CLI = caudal linear nucleus, CPU
= caudate putamen, DG = dentate gyrus, FC = frontal cortex, IPN = interpeduncular nucleus,
LC = locus coeruleus, MH = medial habenula, MT = medial terminal nucleus of the
accessory optic tract, NAcc = nucleus accumbens, NTS-A2, NTS-C2  = nucleus tractus
solitarius, OC = orbital cortex, PC = piriform cortex, PaC = parietal cortex, PVN =
hypothalamic paraventricular nucleus, SC = superior colliculus, SMN = supramamillary
nucleus, SON = supraoptic nucleus, ThN = anteroventral and lateroposterior thalamic nuclei,
VTA = ventral tegmental area.
c-fos = Northern gel analysis for c-fos mRNA, Fos = Fos protein immunohistochemistry.
It has been reported that the pattern of Fos-labeling is dependent upon both the route
and mode of drug administration (Bullitt 1990; Hunt et al. 1987). Only in one study
has the nature of the Fos-positive neurons activated by acute administration of nicotine
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been determined. In this report the neurons of the ventral midbrain area, in which acute
nicotine increased the number of Fos-positive nuclei, were not found to be
dopaminergic (Ren and Sagar 1992). In many brain areas nicotine-induced c-fos
expression is blocked by mecamylamine which suggests its mediation by central
nAChRs (Kiba and Jayaraman 1994; Pang et al. 1993; Ren and Sagar 1992).
2.3.3 Intermittent nicotine administration, Fos and Fos-related antigens
There are very few studies concerning the effect of chronic nicotine treatment on Fos-
immunostaining. Two studies report the effects of intermittent chronic nicotine
treatment with injections; 0.35 mg/kg s.c 3 times a day for 14 days (Mathieu-Kia et al.
1998) and 0.5 mg/kg s.c. once daily for 12 days (Nisell et al. 1997). In both studies a
challenge dose of nicotine was given next day after intermittent nicotine treatment.
Both studies reported the sensitization of the effect of nicotine on Fos-IS after the
challenge dose in the medial prefrontal cortex (PFC) and in the shell of NAcc. In
addition, Mathieu-Kia and collaborators (1998) reported the sensitization in the Cg,
the PaC and the core of the NAcc. Nisell et al. (1997) also found that the chronic
nicotine treatment itself increased the Fos-IS in the medial PFC.
Merlo Pich and collaborators have studied the effect of nicotine self-administration on
the expression of Fos protein in various brain areas (Pagliusi et al. 1996; Pich et al.
1997; 1998). These authors have compared the effects of self-administered nicotine to
nicotine given with injections (= passive nicotine treatment, same amount that was
self-administered). Nicotine self-administration increased Fos expression in most of
the brain regions that were activated by passive nicotine treatment (Pich et al. 1997), in
particular in the CPU, the shell and the core of NAcc, the lateral septum, the Cg and
the PFC. In contrast to passively administered nicotine, nicotine self-administration
did not increase Fos expression in the hypothalamus, the LC, the DG and the amygdala
(Pagliusi et al. 1996). These differences are important, since immediate early gene
expression can represent both the direct pharmacological effects of nicotine on neural
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networks and the activation of drug-seeking behaviour that controls nicotine-
consumption, which includes the reinforcing properties of nicotine (Pich et al. 1999).
The gene expression maps of the Fos-related antigens (FRAs) expressed in the
terminal fields of the mesocorticolimbic dopaminergic pathway of rats trained for
nicotine self-administration have also been studied (Pich et al. 1997). FRAs consist of
a heterogenous group of proteins of the c-fos family that heterodimerize with members
of the c-jun family to produce AP-1 complexes. FRAs and in particular the 35 kDa
component recently identified as D-Fos, are medium-late onset genes and their
products persist for several days in the nucleus of target neurons (Hope et al. 1994).
The gradual development and long-lasting temporal properties of the chronic FRAs
make them candidates for the transcriptional mediators underlying some of the long-
lasting adaptations such as dependence (Hope et al. 1994). Compared with control rats,
increased expression of FRA immunoreactivity was found in the anterior CG, the PFC,
the NAcc, the medial CPU, but not in the amygdala of rats self-administering nicotine
(Pich et al. 1997). Only in rats self-administering nicotine were selective increases of
activity-dependent FRA signals found in the SC, a region enriched with nAChRs but
with less dopamine receptors, supporting the selectivity of nicotine effects.
2.4 Brain areas in which nicotine activates c-fos
2.4.1 Dopaminergic target areas
Nicotine increases the number of Fos-positive nuclei in most striatal and limbic
dopaminergic target areas, namely in the striatum, NAcc, Cg, ACe and PFC as
discussed in Sections 2.3.2 and 2.3.3. The striatum is usually divided into dorsal
striatum and ventral striatum (including the NAcc). Dorsal striatum receives afferents
from sensorimotor cortex and dopaminergic inputs from the pars compacta of the
substantia nigra (Heimer et al. 1995). The striosomes and matrix are the major
neurotransmitter-specific compartments of the caudate-putamen and have different
input-output connections (Robertson et al. 1991). The NAcc is divided to the core and
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shell regions which are differentially innervated by mesencephalic dopaminergic fibres
and are distinguished by differences in basal and stimulated dopamine levels as well as
in dopamine-mediated synaptic responses (Heimer et al. 1991; Meredith et al. 1992).
The NAcc receives its afferents from cerebral cortex, intralaminar thalamic nuclei and
mesencephalic dopamine cells (Heimer et al. 1995). The core of the NAcc projects to
the dorsolateral part of the ventral pallidum, which in turn projects to the subthalamic
nucleus and substantia nigra. The shell of  the NAcc projects to the ventromedial part
of ventral pallidum, which further projects to the VTA (Deutch and Cameron 1992).
Cg and PFC are among the terminal regions of the mesocorticolimbic DA pathway
(Zilles and Wree 1995). The nicotine-induced increase of Fos expression has been
reported to be mediated via dopamine D1 receptors in striatum (Kiba and Jayaraman
1994), NAcc and PFC (Nisell et al. 1997). Both direct and indirect stimulation of
dopamine receptors increases Fos protein expression, mainly in striatum, after
administration eg. of cocaine or amphetamine (Hughes and Dragunow 1995). Further,
non-competitive NMDA antagonists, CPP and MK-801, have been reported to block
the nicotine-induced increase of Fos expression in striatum and NAcc (Kiba and
Jayaraman 1994). Both NAcc and CPU receive glutamatergic pathways from several
regions of cerebral cortex (Walaas 1981).
ACe forms part of the mesolimbic DA system; it is a major target of the DA pathway
originating largely in the A10 and A9 (Kilts et al. 1988; Loughlin and Fallon 1983)
and provides input to substantia nigra (Gonzalez and Chesselet 1990; Price and
Amaral 1981) whilst also receiving catecholaminergic input from the brainstem (Moore
and Bloom 1979). ACe is involved in several stress-induced behavioural and autonomic
responses (Brown and Gray 1988) that may depend on central catecholamine release.
ACe also influences the secretion of adrenocorticotropin (ACTH) by modifying the
negative feedback of glucocorticoids (Dunn and Whitener 1986). Nicotine may activate
ACe either directly or indirectly by stimulating the dopaminergic or noradrenergic
afferent pathways (Matta et al. 1993). Nicotine might also stimulate the release of
corticotrophin-releasing hormone (CRH) from ACe neurons (Matta et al. 1997).
39
2.4.2 Other brain areas
Superior colliculus (SC) and medial terminal nucleus of the accessory optic tract
(MT). The nicotine-induced Fos expression in visual structures can be mediated via
nAChRs present in high density in MT and on afferent retinal fibers (Clarke et al.
1985b; Prusky and Cynader 1988; Wada et al. 1989). The nicotine receptors in the MT
are predominantly presynaptic (London et al. 1985). Nicotine in all probability acts
presynaptically or in the retina itself to stimulate the release of a neurotransmitter,
possibly glutamate, from retinal ganglia cell axon terminals in the MT (Canzek et al.
1981) and in the SC (Binn 1999). The interaction of nicotine with the components of the
visual system can support the evidence for improved performances in visual information
processing observed in smokers and non-smokers receiving nicotine via cigarette smoke
or subcutaneous injection (Foulds et al. 1996; Parrot and Graig 1992).
Hypothalamic paraventricular nucleus (PVN). Although nicotine is a potent activator
of the HPA axis, as manifested by an increase in serum adrenocorticotropic hormone
(ACTH) and corticosterone levels (Balfour 1989; Balfour et al. 1975; Benwell and
Balfour 1979; Conte-Devolx et al. 1981; Weidenfeldt et al. 1989) nicotine does not
directly act in the PVN. Nicotine indirectly stimulates the release of corticotropin-
releasing hormone (CRH) from the parvocellular region of the PVN (pcPVN) by
acting on brainstem noradrenergic structures in a dose-dependent and regionally
selective manner (Matta et al. 1990b; 1995). The CRH neurons located in pcPVN send
their axons to the portal capillaries in the median eminence and subsequently stimulate
ACTH release from the anterior pituitary gland (Swanson et al. 1983). Systemic or
i.c.v. administration of nicotine induces NA release in the PVN in conscious rats
(Matta et al. 1995; Sharp and Matta 1993) and subsequent ACTH secretion
(Andersson et al. 1983; Matta et al. 1990a; 1990b). Mecamylamine given directly into
the PVN of rats did not antagonize the nicotine-induced elevation of extracellular
noradrenaline (NA) concentrations as measured by in vivo microdialysis (Fu et al.
1997). In contrast, nicotine-induced NA release was blocked when mecamylamine was
administered i.p. or directly into the fourth ventricle. Thus, systemic nicotine was
concluded to act on nAChRs in brainstem catecholaminergic regions rather than on
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presynaptic nAChRs in order to elicit NA release from axon terminals (Matta et al.
1998). Nicotine induces both Fos protein expression (Matta et al. 1993; 1998) and c-
fos mRNA response (Sharp et al. 1993a) in the PVN.
Supraoptic nucleus (SON). Nicotine is well known to elevate systemic vasopressin
levels (Andersson et al. 1983; Zbuzek and Zbuzek 1991). Vasopressin in addition to
regulating fluid and electrolyte balance (Sladek and Sladek 1985) also potentiates the
effects of CRH on ACTH release (Prouxl et al. 1984). Magnocellular neurons, whose
perikarya are located principally within the SON, PVN and accessory nuclei of the
hypothalamus synthesize vasopressin and oxytocin (Silverman and Zimmerman 1983)
whilst cholinergic innervation mediates the vasopressin release within SON (Amstrong
1985). In the SON, microinfusion of nicotine induces Fos protein expression mainly in
the magnocellular vasopressin-releasing neurons (Shen and Sun 1995). Shioda et al.
(1997a) have localized both nAChR a4 subunit mRNA expression and
immunoreactivity in the magnocellular neurons in the SON. Nicotine seems to activate
vasopressin-releasing neurons via nAChRs composed of a4 subunits and has also been
linked to stimulation of the cyclic AMP- protein kinase A-regulated Ca2+-signaling
pathway (Shioda et al. 1997b). On the other hand, nAChR a7 subunit mRNA has been
detected in the SON (Séguéla et al. 1993), and acetylcholine-evoked voltage clamp
currents in the SON were abolished by nAChR a7 subunit selective antagonist
methyllycaconitine but not by dihydro-b-erythroidine, an a4b2 nAChR subunit
selective antagonist (Zaninetti et al. 2000).
Interpeduncular nucleus (IPN). IPN appears to occupy a central position in the
midbrain limbic system (Morley 1986). Most of the connections of the IPN are related
to the neural circuits of the limbic system and its midbrain connections. For example, a
direct pathway has been demonstrated from IPN to the hippocampus, the main
integrative centre of the limbic system (Contestabile and Flumerfelt 1981). Thus, IPN
is one of centres in the network of connections that convey and modulate the input
from the limbic forebrain regions to the limbic midbrain area (Contestabile and
Flumerfelt 1981), and is not only involved in avoidance and emotional behaviour
(Morley 1986) but also in arousal (Hentall and Gollapudi 1995). It has been reported
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that IPN partly mediates the nicotinic depression of locomotor activity and is involved
in dampening the nicotinic arousal mechanisms (Hentall and Gollapudi 1995). In
humans, nicotine’s effects have been found to depend on the baseline level of arousal
at the time an individual uses tobacco (Rosecrans and Karin 1997).
The cholinergic habenulo-interpeduncular pathway, i.e. the neurons sending their
axons from medial habenula to the IPN, possesses high density of 3H-nicotine binding
sites (Clarke et al. 1985b; London et al. 1985), that are either pre- or postsynaptic
nAChRs (Brown et al. 1984; Mulle et al. 1991). The IPN strongly expresses mRNAs
for a2, a3, a4, a5, a7, b2 and b4 nAChR subunits (Deneris et al. 1989a; Séguéla et
al. 1993; Wada et al. 1989; 1990a). Moreover, in a quantitative in vivo 3H-nicotine
binding study the density of nicotinic binding sites in IPN was one of the highest of
any brain region assayed (London et al. 1985).
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3 AIMS OF THE STUDY
The main purpose of this study was to investigate in vivo the functional changes
(desensitization and long-lasting inactivation) induced by chronic nicotine infusion
and withdrawal in the nAChRs involved in the mediation of nicotine’s central effects.
The detailed aims were:
To map the brain areas activated by systemic administration of acute nicotine using an
immunohistochemistry procedure to estimate the expression of Fos protein encoded by
immediate-early gene c-fos in rats. To clarify further the nature of nicotine-induced
Fos protein expression in brain areas that are likely to be involved in coping with
stress. The neural pathways activated by nicotine were studied by examining possible
interaction of diazepam and nicotine on their ability to induce Fos-expression (I).
To investigate the presynaptic effects of chronic nicotine infusion and withdrawal on
nicotine-induced changes in dopaminergic transmission by determining the
concentrations of dopamine and its metabolites in various brain areas of rats and mice
(II, IV). To further determine the nature of reduced response to nicotine –
desensitization or tolerance which is overcome by increasing the dose – the
hypothermic response of mice to nicotine was determined during chronic infusion
(IV).
To evaluate how chronic nicotine treatment and its withdrawal influence the acute
nicotine-induced Fos protein expression in various rat brain areas (II, III). In
particular, the immunostaining of Fos protein in dopaminergic target areas was studied
to determine whether the nicotine-induced changes in dopamine metabolism could be
detected in postsynaptic neurons at the level of immediate-early gene producs (II).
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4 MATERIALS AND METHODS
The methods used have been described in detail in the respective communications.
4.1 Animals
Male Wistar rats (I, II, III) and male HsdHan:NMRI mice developed at the National
Marine Research Institute (Bethesda, MD, USA) (IV) were used. Animals were bred
locally in the Laboratory Animal Centre of the University of Helsinki. Mice were
housed in groups of six to eight and rats in groups of four to six in a cage at an ambient
temperature of 20-22 °C. The animals had ad libitum access to standard diet and tap
water. The experimental protocols were approved by the Committee for Animal
Experiments of the Faculty of Science of the University of Helsinki.
4.2 Experiments
4.2.1 Chronic administration of nicotine
Nicotine was administered chronically via osmotic minipumps (rats) and via nicotine-
releasing reservoirs (mice). Osmotic minipumps (Alzet 2001) containing saline
(= sham-operated rats) or nicotine hydrogen tartrate solutions (= nicotine-infused rats)
were implanted subcutaneously to rats under halothane anesthesia (II, III). Nicotine
was infused at a dose of 4 mg/kg/day for 7 days. The dose refers to the base. Rats were
housed singly after surgery. To mice (-) - nicotine was administered chronically for 7
days using subcutaneously implanted nicotine releasing reservoirs (IV) as described
for rats by Erickson et al. (1982) which were modified for treatment of mice according
to Leikola-Pelho et al. (1990). Control mice were sham-operated under the same
experimental conditions i.e. s.c. implanted reservoirs contained saline instead of
nicotine. Mice were housed in original groups after surgery.
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4.2.2 Withdrawal from nicotine treatment
In rats withdrawal was induced by removing the minipumps surgically on the seventh
day of chronic nicotine treatment. In mice the removal of implanted reservoirs in order
to induce withdrawal proved to be impossible due to tissue growth at the lesioned site.
4.2.3 Nicotine challenge experiments
For injections, (-)-nicotine base was diluted with saline (0.9% NaCl solution), and the
pH of the final solution was adjusted to 7.0 – 7.4 (I - IV). 10 - 12 week-old rats were
given single acute doses of 0.5 and 1 mg/kg nicotine or saline subcutaneously (I). To
prevent the peripheral effects of nicotine, which are likely to occur with the dose of 1
mg/kg, rats were pretreated with hexamethonium (10 mg/kg, i.p.) dissolved in saline.
Rats were perfused intracardially 60 min after the acute nicotine administration and
brains were prepared for immunohistochemistry.
Rats received either saline or acute nicotine (0.5 mg/kg s.c.) 60 min before
decapitation (II) or intracardial perfusion (II, III) on the seventh day of nicotine
infusion with the minipumps still in place and after 24-h or 72-h withdrawal. Mice
received either saline or acute nicotine (1 or 2 mg/kg s.c.) 60 min before decapitation
on the seventh day of the infusion with the reservoirs still in place (IV). The acute
challenge experiments were performed at an ambient temperature of 20-24 °C.
4.2.4 Measurement of rectal temperatures
The rectal temperatures of mice (IV) were measured on the seventh day of chronic
treatment (either saline- or nicotine-infused mice) before and at 30 and 60 min after
acute challenge injection (saline or nicotine). The rectal temperatures were measured
with an electric thermocouple (Ellab Instruments, Copenhagen, Denmark) inserted
2.5 cm into the rectum. DT is the mean difference of rectal temperatures measured
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before an acute injection and 30 or 60 min after acute treatment, the last measurement
being immediately before decapitation.
4.2.5 Dissection of brain
Mice and rats were killed by decapitation and their brains rapidly removed. After
decapitation of rats the striatum and limbic forebrain (containing inter alia the
olfactory tubercles, medial part of the nucleus accumbens, the central nucleus of
amygdala and part of the paleocortex) were dissected on an ice-cold plate and
collected on dry ice within 5 min (II). The striata of mice were dissected and frozen
within 3 min (IV). The striatal brain area dissected from the mice consisted of dorsal
striatum as well as ventral striatum, which included the nucleus accumbens. Tissues
were weighed and stored at - 80 °C until assayed.
4.2.6 Preparation of plasma samples
Before collecting and preparing the blood samples (II, IV), all laboratory equipment
was carefully rinsed with ethanol (99.9% w/w) and kept in an oven at 40-100 ºC for at
least 12 h before use in order to remove nicotine contamination. After decapitation, the
trunk blood of the mice and rats was collected and the plasma separated from blood by
centrifugation. The plasma samples were stored at - 80 ºC until assayed. The samples
were prepared as described by Curvall et al. (1982) with slight modifications, as
described earlier by Leikola-Pelho et al. (1990) and Pekonen et al. (1993).
4.2.7 Preparation of brain sections for immunohistochemistry
The nicotine- or saline-infused rats received saline or 0.5 mg/kg of nicotine s.c. one
hour before the pentobarbital (100 mg/kg, i.p.; Orion Pharma, Espoo, Finland, 5-10
min before perfusion). The experiments were performed under the same conditions i.e.
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control and nicotine-treated rats were handled similarly, at the same time of the day
and room temperature was always the same. Rats were always injected in another
room than the one where the perfusions were carried out to minimise stress. Rats were
then perfused intracardially with 0.9% phosphate-buffered saline (PBS) followed by
4% paraformaldehyde in 0.1 M sodium phosphate buffer (PB) pH 7.4. The brains were
dissected out and postfixed with the same fixative for 4 h at room temperature. The
brains were immersed in a 20% sucrose solution at 4 °C until used. The 40 mm sections
were cut on a cryostat.
4.2.8 Drugs
The drugs were (-)-nicotine base (Fluka AG, Buchs, Switzerland), nicotine
hydrogentartrate (Sigma Chemical Company, St. Louis, Missouri, USA),
hexamethonium hydrobromide (Fluka AG, Buchs, Switzerland) and diazepam
(Diapam® 5 mg/ml inject, Orion Pharma, Espoo, Finland).
4.3 Analytical methods
4.3.1 Estimation of plasma concentrations of nicotine and cotinine using GC-MS
(II, IV)
The concentrations of nicotine and its main metabolite cotinine were determined by a
gas chromatographic-mass spectrometric (GC-MS) method using selected ion
monitoring (SIM) as earlier described by Leikola-Pelho et al. (1990) and Pekonen et
al. (1993). GC-MS analyses were performed on an Hewlett Packard 5970 quadrupole
MS coupled to an Hewlett Packard 5890 GC using an SE-54 fused silica column (15
m). In the GC-MS analyses fragment ions of m/z 84 (nicotine), 98 (cotinine) and 129
(quinoline) were used.
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4.3.2 Measurement of tissue contents of do pamine and its metabolites using
HPLC-EC (II, IV)
The striatal (II, IV) and limbic (II) concentrations of DA and its metabolites DOPAC
and HVA were measured using high-performance liquid chromatography (HPLC) with
electrochemical detection after Sephadex G-10 gel chromatographic clean-up of
samples. Tissue samples were homogenised in 1 ml 0.2 M HClO4, and pH of the
homogenates was adjusted to 2.4 by KOH/HCOOH buffer. After centrifugation
(15 min, 28 000 x g, 4°C) 1 ml of supernatant was put on an acidic (0.01 M HCl)
Sephadex G-10 column (bed height 8 mm) prepared in a long Pasteur pipette. After the
supernatants had passed through the columns, the compounds were eluted, and a
200 ml portion of each collected fraction was injected through a high-pressure injection
valve in a HPLC column. The C-18 reverse phase (Spherisorb ODS 2 mm) HPLC
column (25 cm, 4.6 mm i.d.) was connected to the electrochemical detector
(Coulochem II, ESA). The assay is described in detail by Haikala (1987).
4.3.3 Fos-immunohistochemistry (I, II, III)
In Study I the sections were first incubated in 1.5% normal goat serum (in 0.1 M PB)
for 60 min to block non-specific staining. Sections were then incubated in primary fos-
antibody diluted 1:2000 in PBS (pH 7.2; 0.1% sodiumazide) for 14 - 16 h at room
temperature. Sections were processed with the avidin-biotin method (Vectastain Kit,
Vector Laboratories, Burlingame, CA) with diaminobenzidine (Sigma Chemicals,
St.Louis, MO, USA) as the chromagen, mounted on gelatine/chrome alume-coated
slides, air dried, dehydrated through graded ethanols to xylene and coverslipped with
DePex (BDH Laboratory Supplies, Poole, U.K.). For the Studies II and III and study
described in section 5.4.1 we had to change the staining protocol due to the problems
with excessive background staining with new lots of primary antibody. Also, different
counting method for the Fos-positive nuclei was used. The sections were first
incubated in 2% normal rabbit serum (NRS, Vector Laboratories, Burlingame, CA,
USA; in PBS + 0.5% Tween 20) for 60 min to block non-specific staining. The
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sections were then incubated in primary fos-antibody diluted in 1:1000 (experiments
during chronic nicotine) or 1:2000 (withdrawal experiments) in PBS (in 0.5% Tween
20 + 4% NRS) for 72 h at 4°C. The sections were processed with the avidin-biotin
method with diaminobenzidine as above. The sections were processed and mounted as
described above.
The primary antibody used was a sheep polyclonal antibody to fos oncoproteins to a
synthetic peptide with amino-acid sequence: Met - Phe - Ser - Gly - Phe - Asn - Ala -
Asp - Tyr - Glu - Ala - Ser - Ser - Ser - Arg - Cys, selected from a conserved region of
mouse and human c-fos N-terminal (van Straaten et al. 1983). This sequence has no
homology with other members of nuclear transcription factors recently cloned
(Mathieu-Kia et al. 1998). The Fos-antibody was obtained first from Cambridge
Research Biochemicals, UK (OA-11-823, OA-11-824), then later, after the company
had changed its name, Genosys Biotechnologies Inc., UK (OA-11-824). Controls for
the immunostaining, which included omission of either primary or secondary antibody,
demonstrated no Fos-immunostaining. OA-11-823/824 has been used widely in the
literature and the primary preabsorbtion with purified antigen, which demonstrated no
Fos-IS, has been done several times (Bernard et al. 1993; Berretta et al. 1992; Graybiel
et al. 1990; Johnson et al. 1992).
In Study I the number of Fos-positive nuclei was counted manually using a light
microscope at 10 x magnification. A group mean (± S.E.M) was determined from the
counts of 3 - 4 rats in each treatment group. In the subsequent studies the Fos-positive
nuclei were counted with a 10x objective with the assistance of a LEICA QWin image
analysis system on selected brain areas within a rectangular area of 480 x 360 mm2. A
group mean (± S.E.M) was determined from the counts of 4 - 7 rats in each treatment
group. The mean number of Fos-positive nuclei of both hemispheres was calculated
from one of three adjacent sections, but all three were visually inspected under
microscope and were required to show similar pattern of Fos IS. The atlas of Paxinos
and Watson (1986) was used to identify the brain areas in all three studies (Table 4.1).
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Table 4.1 Rat brain areas where the Fos-immunostaining was determined.
Brain area Plate Co-ordinates
AP DV
Cingulate cortex 11 -1.0 -3.0
Nucleus accumbens 13-14 -1.2 -6.6
Caudate-putamen 17 -1.8 -3.6
Central amygdala 29 -4.0 -8.0
Paraventricular nucleus 25 0 - -1.0 -8.0
Supraoptic nucleus 23 -1.8 -9.6
Medial terminal nucleus 39 -1.2 -8.0 - -9.0
Interpeduncular nucleus 41 0 -9.0
AP = anterior-posterior; DV = dorsal-ventral. Paxinos and Watson (1986).
4.3.4 Statistical analysis
As the the concentrations of dopamine and its metabolites (II, IV) were estimated in
several separate experiments, the statistical analyses were carried out by three-way
analysis of variance (ANOVA) (experiment x chronic treatment x acute challenge). As
no significant interactions between the experiment and other factors were observed,
the randomised block two-way ANOVA was performed using experiments as blocks.
If there were significant chronic x acute nicotine interactions (P<0.1), the analysis was
continued by comparing appropriate cell means with linear contrasts. The Fos-
immunostaining data were analysed by Kruskall-Wallis nonparametric ANOVA
followed by the Mann-Whitney U-test (I, II) and by two-way ANOVA followed by
linear contrast analysis (II, III). The effect of nicotine challenge doses on rectal
temperatures was analysed by two-way ANOVA for repeated measurements. As
significant chronic x acute x time interactions (P<0.1) were found, the Tukey’s post
hoc comparisons at timepoints were made (IV). The data concerning plasma nicotine
and cotinine concentrations were analysed by Student’s t-test (II, IV).
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5 RESULTS
5.1 The plasma concentrations of nicotine and cotinine in rats and mice (II,
IV)
The plasma concentrations of nicotine and cotinine in rats and mice treated acutely and
chronically with nicotine as well as withdrawal of nicotine in rats are summarised in
Table 5.1. The nicotine and cotinine concentrations both in rats and mice were clearly
elevated on the seventh day of chronic nicotine infusion.
Table 5.1 The plasma concentrations of nicotine and cotinine on the seventh day of
chronic treatment (saline or nicotine) and at 1 h after nicotine administration in rats
and mice . Also shown are the concentrations at 1 h after nicotine administration in
rats withdrawn of nicotine (24 h).
RATS Saline-infused Nicotine-infused
Acute
treatment
Nicotine (ng/ml) Cotinine (ng/ml) Nicotine (ng/ml) Cotinine (ng/ml)
On the 7th
day
Saline 0 0 76 ± 7 858  ± 142
Nicotine
(0.5 mg/kg)
80  ± 22 103  ± 25 114  ± 24 639  ± 106
After 24 h
withdrawal
Saline 0 0 0 22  ± 12
Nicotine
(0.5 mg/kg)
78  ± 6 119  ± 15 79  ± 6 149  ± 15
MICE Saline-infused Nicotine-infused
Acute
treatment
Nicotine (ng/ml) Cotinine (ng/ml) Nicotine (ng/ml) Cotinine (ng/ml)
On the 7th
day
Saline 0 0 207  ±  32 1366  ± 258
Nicotine
(1 mg/kg)
96  ± 14 222  ± 31 301  ± 56 1861  ± 253
Nicotine
(2 mg/kg)
421  ± 35 1529  ± 284
The results are from Study II and IV, and unpublished (nicotine 2 mg/kg in mice).
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In rats, acute nicotine did not clearly increase the plasma nicotine or the cotinine
concentrations with nicotine-releasing minipumps still in place. Further, at 24 hours
after removal of the minipumps no nicotine and only traces of cotinine were found in
the plasma. Acutely administered 0.5 mg/kg nicotine elevated the plasma nicotine and
cotinine concentrations in the withdrawn rats to the same degree as in the control rats.
In mice, the plasma nicotine concentrations measured on the seventh day of the
chronic nicotine treatment with nicotine-releasing reservoirs still in place agree well
with the previous results of Leikola-Pelho et al. (1990).
5.2 Nicotine-induced hypothermia in mice (IV)
During the 7-day chronic nicotine administration the rectal temperatures of nicotine-
infused mice did not differ significantly from those of the saline-infused control mice.
The effects of acute nicotine administration (1 and 2 mg/kg s.c.) on rectal temperatures
of both saline-infused control and nicotine-infused mice are shown in Fig. 5.1.
Figure 5.1 The effects of 1 mg/kg and 2 mg/kg of acute nicotine on the body temperature of
the control mice and of the nicotine-infused mice at an ambient temperature of 20-22°C. The
means ± S.E.M of 12-15 mice are shown. The asterisks show the significant differences
(* P<0.05, ** P<0.01) between acute nicotine administration and control mice, the circle
shows significant difference (o P<0.05) between acute nicotine administration and chronic
nicotine infusion.
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Attenuation of the acute nicotine-induced hypothermia during chronic nicotine
infusion was observed at 30, but not at 60 min after injection. Thus, the nicotine-
infused mice recovered more slowly from hypothermia than the saline-infused mice.
The acute nicotine dose of 1 mg/kg decreased the rectal temperature of nicotine-
infused mice significantly less than that of control mice. The dose of 2 mg/kg
decreased the rectal temperature of nicotine-infused mice to a similar level as found in
control mice.
5.3 The tissue concentrations of dopamine and it metabolites, DOPAC and
HVA
5.3.1 The effect of nicotine challenge during chronic nicotine administration in
mice and rats (II, IV)
The effect of acute nicotine challenge given on the seventh day of chronic nicotine
infusion on dopamine metabolites DOPAC and HVA in mice and rats is summarised
in Table 5.2. Both in saline-infused control mice and rats the acute challenge doses of
nicotine increased the striatal concentrations of DOPAC and HVA. In mice dose-
dependency was studied and indeed, it was found that 1 mg/kg of nicotine only
increased striatal DOPAC, whereas the 2 mg/kg dose increased both DOPAC and
HVA concentrations. In rats, it was possible to assay the concentrations of DOPAC
and HVA in limbic brain areas separately and in this case a 0.5 mg/kg dose of nicotine
increased both DOPAC and HVA more clearly (limbic DOPAC by 49 - 70% and
HVA by 66 - 86%) than in striatal brain areas (striatal DOPAC by 24 - 40% and
HVA by 20 - 46%).
Neither in mice nor in rats did nicotine increase striatal DOPAC and HVA
concentrations when acute nicotine challenge was given on the seventh day of chronic
nicotine infusion (Table 5.2, II; Fig. 2, IV; Fig. 1). In contrast, in the limbic areas of
rats acute nicotine somewhat increased, but significantly less than in the control rats,
HVA concentration although it did not elevate DOPAC concentration on the seventh
day of chronic infusion (Table 5.2, II; Fig.3).
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Chronic nicotine treatment itself did not alter striatal DOPAC and HVA concentrations
either in rats or in mice (II; Fig. 2, IV; Fig. 1). Instead, limbic HVA concentration was
significantly elevated in rats with minipumps still in place (II; Fig. 3). Striatal and
limbic DA concentrations were not altered by any of the treatments in either rats or in
mice (II; Figs. 2 and 3, IV; Fig.1).
Table 5.2 The effect of acute nicotine given on the seventh day of chronic nicotine or
saline infusion on striatal and limbic dopamine metabolites, DOPAC and HVA, in
mice and rats.
MICE RATS
STRIATAL STRIATAL LIMBIC
DOPAC HVA DOPAC HVA DOPAC HVA
Acute nicotine to saline-infused control animals
0.5 mg/kg - - ­­­ ­­ ­­ ­­­
1 mg/kg ­­ 0 - - - -
2 mg/kg ­­­ ­­ - - - -
Acute nicotine on the seventh day of chronic nicotine infusion
0.5 mg/kg - - 0*** 0** 0 ­­*
1 mg/kg 0** 0 - - - -
2 mg/kg 0*** 0** - - - -
Table summarises the results from Study II (Figs. 2 and 3) and from Study IV (Fig. 1).
The arrows show significant increases by acute nicotine: ­­  P<0.01 and ­­­
P<0.001. The asterisks show the significant differences (** P<0.01, *** P<0.001)
between nicotine-treated and control animals at 60 min after an acute nicotine
challenge dose given s.c. (linear contrasts after 2-way randomised block ANOVA). A
dash (-) indicates not measured, 0 indicates no change induced by acute nicotine.
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5.3.2 The effect of nicotine challenge on rats withdrawn from chronic nicotine
administration (II)
The effect of an acute nicotine challenge on the striatal and limbic dopamine
metabolites DOPAC and HVA in nicotine-withdrawn rats (24 h and 72 h) is
summarised in Table 5.3.
Nicotine-withdrawal did not alter striatal or limbic DA, DOPAC and HVA
concentrations (II; Figs. 2 and 3). At 24 h and at 72 h after removal of the minipumps,
acute nicotine significantly elevated striatal DOPAC and HVA in the nicotine-infused
rats to almost the same extent as in the saline-infused rats. Acute nicotine
administration did not elevate the limbic DOPAC concentration after 24-h withdrawal,
but after 72-h withdrawal DOPAC concentrations were found to have increased. After
24-h and 72-h withdrawal the nicotine-induced elevations of HVA in the nicotine-
infused rats were similar to those of the controls.
Table 5.3 The effect of an acute nicotine challenge (0.5 mg/kg s.c. 60 min) on the
striatal and limbic dopamine metabolites, DOPAC and HVA at 24 and 72 h after
removal of the osmotic nicotine-releasing minipumps (= nicotine-withdrawn rats).
STRIATAL LIMBIC
DOPAC HVA DOPAC HVA
Acute nicotine to saline-infused control rats
­ or ­­ ­ or ­­ ­­­ ­­­
Acute nicotine in nicotine-withdrawn rats (24 h)
­ ­­ 0* ­­
Acute nicotine in nicotine-withdrawn rats (72 h)
­ ­ ­­ ­­
Table summarises the results from Study II (Figs. 2 and 3). The arrows show
significant increases of acute nicotine: ­  P<0.05; ­­  P<0.01 and ­­­  P<0.001. The
asterisk shows the significant difference (* P<0.05) between nicotine-treated and
control animals at 60 min after an acute nicotine challenge dose given s.c. (linear
contrasts after 2-way randomised block ANOVA). 0 indicates no change induced by
acute nicotine.
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5.4 The expression of Fos protein in rat brain areas
5.4.1 Naïve and saline-injected rats (unpublished results)
To test whether injection and handling before perfusion affected the number of Fos-
positive nuclei in different rat brain areas, two rats were given saline s.c. (0.2 ml/100g)
and perfused thereafter along with two rats that underwent perfusion only (Table 5.4.).
All rats were given pentobarbital (100 mg/kg i.p.) 10 min before perfusion.
Table 5.4 The number of Fos-positive nuclei in different brain areas in naïve and
saline-treated male Wistar rats.
Saline-injected rats Naïve rats
rat I rat II rat I rat II
SON 0/0 0/0 0/0 0/0
MT 0/0 5/16 0/0 8/3
IPN 1 21 14 8
VLG 0/0 0/0 0/0 0/0
ACe 0/0 5/6 0/0 0/0
PVN 18/13 14/16 19/18 8/11
The figures give numbers of nuclei counted on left/right side of the brain.
ACe = central nucleus of amygdala, SON = supraoptic nucleus, PVN = hypothalamic
paraventricular nucleus, MT = medial terminal nucleus of the accessory optic tract,
VLG = ventral lateral geniculate and IPN= interpeduncular nucleus.
5.4.2 Acute nicotine (I and unpublished results)
In study I, an acute dose of 1 mg/kg of nicotine (s.c. 60 min; pretreated with
hexamethonium to prevent the nicotine-induced hypoxia) tended to increase Fos
immunostaining  (Fos IS) in the interpeduncular nucleus (IPN; number of Fos-positive
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nuclei 115 ± 34, mean ± SEM, n=3) as compared with control rats treated with saline
(+ hexamethonium) under the same conditions (45 ± 2, n=3). In the medial terminal
nucleus of the accessory optic tract (MT) where Fos-positive nuclei were found in only
one control animal, the increase from 1 ± 1 (n=4) to 96 ± 23 (n=4) was statistically
significant (P<0.01) (I, Fig. 1). Fos IS was also studied in two other areas in the central
visual system: no Fos IS was detected in the superior colliculus (SC) of either control or
nicotine-treated rats. Nicotine did not increase the number of Fos-positive nuclei in the
ventral lateral geniculate nucleus (VLG; saline: 39 ± 15, NIC: 32 ± 8, n=4). Nicotine
tended to increase Fos IS in the stress-related hypothalamic paraventricular nucleus
(PVN; NIC: 336 ± 54 vs. saline: 281 ± 33, n=4) (I, Fig. 2 and 3) and supraoptic nucleus
(SON; NIC: 89 ± 7 vs. saline: 44 ± 19, n=4) (I, Fig. 2 and 4). Nicotine did not induce
Fos IS in the central nucleus of amygdala (ACe; 100 ± 13, n=4) as compared with
control rats (95 ± 21, n=4) (I, Fig. 2 and 5).
Table 5.5 The effect of an acute nicotine challenge (0.5 mg/kg, s.c., 60 min) on the
number of Fos-positive nuclei (mean ± S.E.M.) in various brain areas of male Wistar
rats as compared with saline-treated control rats.
PFC Cg NAcc CPU ACe
Control 38.5± 4.0 54.0±13.2 28.2±2.7 15.2±4.7 15.2±5.2
Acute
nicotine
66.8± 7.8 88.0±9.6 81.7±10.2** 44.0±11.0* 74.0±22.1*
SON PVN MT SC IPN
Control 11.5±2.0 35.5±5.7 0.5±0.2 2.8±0.9 1.2±0.6
Acute
nicotine
60.3±11.5** 373.5±40.4** 86.0±8.3** 166.2±13.9** 162.5±9.5**
*P<0.05, **P<0.01 (Kruskall-Wallis followed by Mann-Whitney U-test), n= 5-6.
PFC = prefrontal cortex, Cg = cingulate cortex, NAcc = core of nucleus accumbens ,
CPU = dorsomedial caudate-putamen, ACe = central nucleus of amygdala, SON =
supraoptic nucleus, PVN = hypothalamic paraventricular nucleus, MT = medial
terminal nucleus of the accessory optic tract, SC = superficial gray layer of superior
colliculus and IPN= interpeduncular nucleus.
Table 5.5 summarizes the results obtained from rats treated with a challenge dose of
0.5 mg/kg, s.c., 60 min (unpublished). This challenge dose was later used in the
chronic nicotine and withdrawal experiments. With this smaller nicotine dose the
critical signs of hypoxia were not seen and therefore, the administration of
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hexamethonium, which might interfere with the nicotine’s effects on Fos expression,
was not necessary. When hexamethonium was not used, nicotine elevated Fos IS
significantly in all brain areas studied, except in the PFC and in the Cg. On
examination of the dopaminergic target areas, the increase of Fos-expression by acute
nicotine occurred mainly in the core part of the NAcc, whereas no change in the
number of Fos-positive nuclei was observed in the shell (Data not shown). Therefore,
Fos-positive nuclei were only counted in the core of NAcc.
5.4.3 Acute nicotine and diazepam (I)
Table 5.6 summarizes the results from an acute study in which the effects of 1 mg/kg
of nicotine (s.c.) were studied in rats pretreated with 10 mg/kg diazepam (i.p.).
Table 5.6 The changes in the number of Fos-positive nuclei (calculated as percentages
of corresponding controls) in different rat brain areas after acute nicotine and/or acute
diazepam.
TreatmentBrain area
nicotine (nic) diazepam (diaz) nic + diaz
SON + + + + + + + + + + + +
PVN + + + + + +
MT + + + + + + + + + + + + + +
IPN 0 - - 0
VLG 0 + + + +
ACe + + + + + +
For abbreviations see Table 5.4
0      0 - +20% + + + + +100 - +500%
+ +20 - +50% + + + + + +500 -
+ + +50 - +75% - -    -50 - -75%
+ + + +75 - +100%
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5.4.4 Chronic nicotine-infusion and withdrawal (II, III)
During 7-day chronic nicotine infusion
The effects of an acute nicotine challenge dose given on the seventh day of chronic
saline- or nicotine infusion on Fos expression were studied in the brain areas shown in
Table 5.7. Constant nicotine infusion itself did not alter the Fos-IS in any of the brain
areas studied.
On the seventh day of chronic nicotine infusion the effect of acute nicotine on the
number of Fos-positive nuclei varied, as shown in Table 5.7. In the PVN, SON and
CPU of rats infused chronically with nicotine, acute nicotine had no effect. In the
NAcc and IPN there was an increase of Fos-immunostaining (IS) which, however, was
significantly less than in saline-infused control rats. In the ACe and Cg acute nicotine
increased Fos-IS in nicotine-infused rats to the same extent as it did in saline-infused
rats.
Table 5.7 The effect of an acute nicotine (0.5 mg/kg s.c. 60 min) on Fos-immuno-
staining in various brain areas of control and nicotine-treated rats on the seventh day of
chronic nicotine infusion (4.0 mg/kg/day) with the minipumps still in place.
PVN SON CPU NAcc IPN Cg ACe
Acute nicotine on the seventh day of saline-infusion
­­­ ­­ ­­­ ­­­ ­­­ ­­­ ­­­
Acute nicotine on the seventh day of chronic nicotine infusion
0*** 0*** 0*** ­*** ­­­*** ­­ ­­­
Table summarises the results from Study II (Fig. 4) and from Study III (Fig. 1). The arrows
show significant increases of acute nicotine: ­  P<0.05, ­­  P<0.01 and ­­­  P<0.001.
0 indicates no change induced by acute nicotine as compared with corresponding acute saline
controls. The asterisks show the significant differences (*** P<0.001) between nicotine-
treated and control animals at 60 min after an acute nicotine challenge dose given s.c.. The
statistical values were calculated by 2-way ANOVA followed by linear contrasts and thus the
signicances somewhat differ from Study II, Fig. 4.
CPU = dorsomedial caudate-putamen,  NAcc = core of nucleus accumbens, Cg  = cingulate
cortex, ACe = the central nucleus of amygdala, IPN = interpeduncular nucleus, PVN =
hypothalamic paraventricular nucleus, SON = supraoptic nucleus.
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Nicotine withdrawal
Neither 24-h nor 72-h withdrawal from nicotine altered the number of Fos-positive
nuclei in the CPU, NAcc, Cg and ACe (II, Fig. 4) and 72-h withdrawal did not alter
Fos expression in the PVN, SON or IPN (III, Fig.1). No increases of Fos-IS were seen
in the CPU, in the NAcc or in the Cg when acute nicotine was given to rats withdrawn
for 24 h from 7-day nicotine infusion. However, in the ACe of these nicotine-
withdrawn rats acute nicotine increased Fos IS in the same way as in control rats (II,
Fig. 4). At 72 h after removal of the nicotine-releasing minipumps acute nicotine
elevated Fos IS in the same way as in control rats in all seven brain areas studied (II,
Fig. 4 and III, Fig. 1).
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6 DISCUSSION
6.1 The plasma concentrations of nicotine and cotinine
Osmotic minipumps release nicotine steadily throughout the period they are intended
to be used when implanted in rats. In this study we used minipumps designed for 7-day
administration so that on the seventh day the plasma nicotine concentration was 76 ±
7 ng/ml (n=7) at an infusion rate of 4 mg/kg/day. This correlates well with the study of
Benwell et al. (1995) where they used minipumps designed for 14-day administration.
These authors obtained the plasma concentrations of nicotine 87 ± 12 ng/ml on the
14th day of the infusion at the rate of 4 mg/kg/day. The dose of chronic nicotine
(4 mg/kg/day) resulted in plasma nicotine levels similar to peak levels found in arterial
blood following the inhalation of smoke from cigarettes (Henningfield et al. 1993).
The plasma nicotine concentrations on the seventh day of infusion were almost
equivalent to plasma concentrations found at 60 min after one single injection of
nicotine (0.5 mg/kg, s.c., Study II, Table 1). It has been reported that brain levels of
nicotine were about three times higher than those in the blood (Benowitz 1990; Rowell
and Li 1997; Sastry et al. 1995). Thus, the plasma nicotine concentrations determined
in this study implicate high cerebral nicotine concentrations in rats.
Earlier, in our laboratory Leikola-Pelho and collaborators (1990) determined the
plasma concentrations of nicotine and cotinine in mice chronically infused with
nicotine using the same administration protocol as in Study IV. Chronic nicotine was
administered via subcutaneously implanted nicotine-releasing reservoirs for 1 – 29
days. During the first seven days of chronic infusion, nicotine concentrations in the
plasma decreased steadily from a peak value of 480 ng/ml to 200 ng/ml (Leikola-Pelho
et al. 1990). In Study IV the plasma concentrations of nicotine in mice obtained on the
seventh day with the reservoirs still in place (207 ± 32 ng/ml, n=12) correlate well
with the results of Leikola-Pelho et al. (1990). The determination of plasma nicotine
and cotinine concentrations is essential when comparing the nicotine-induced changes
in these two studies, because the reservoirs used were home-made. When compared to
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rats or humans, a higher dose of nicotine is required in mice because of the rapid
metabolism of nicotine in mice (Rowell and Li 1997).
6.2 Nicotine-induced elevation of striatal and limbic DOPAC and HVA
concentrations
In this study the striatal and limbic concentrations of DA and its metabolites DOPAC
and HVA were estimated in rats and the striatal ones in mice. The advantage of
estimating the post mortem tissue concentrations of dopamine metabolites is that
enables us to study the dopaminergic transmission simultaneously from several brain
areas and from animals that have not experienced extra surgery and anaesthesia. In this
respect, the animals are experimentally naïve. There are disadvantages of this method,
in that it is not possible to study the time-course of drug-induced alterations in
neurotransmitter release in one animal and to correlate the changes of neurotransmitter
release in real time with the behaviour of the animal. Furthermore, in mice very few
studies have utilized the in vivo microdialysis technique to determine DA metabolism,
since accurate implantation of probes in mouse brain coupled with measurement of
DA and its metabolism in the extracellular fluid sensitively enough is difficult to
accomplish.
In agreement with the study of Grenhoff and Svensson (1988) acute nicotine
(0.5 mg/kg, s.c.) in rats (II) elevated the tissue concentrations of limbic dopamine
metabolites somewhat more than those measured in striatum.
In sham-operated mice both acute nicotine doses (1 and 2 mg/kg) increased DOPAC
concentration, and the larger acute dose of 2 mg/kg also increased HVA. These
findings agree with those of Haikala et al. (1986) in that striatal DOPAC concentration
is more susceptible to the effects of nicotine than striatal HVA. Thus, it could be that
nAChRs involved in the regulation of the intraneuronal DA metabolism differ in their
sensitivity from those involved in impulse-mediated DA release as suggested by
Leikola-Pelho et al. (1990). The differences we found in the effect of acute nicotine on
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limbic DOPAC and HVA concentrations both in nicotine-treated and nicotine-
withdrawn rats, (see Tables 5.2 and 5.3) further support this hypothesis.
6.3 The effect of chronic nicotine and its withdrawal on the nicotine-induced
changes in cerebral dopamine metabolism
6.3.1 The desensitization of nAChRs regulating cerebral dopamine metabolism
The nicotine-induced elevations of the limbic DOPAC and HVA were reduced when
acute nicotine was given to rats infused with nicotine. These findings agree with
microdialysis studies done in rats (Benwell and Balfour 1997; Benwell et al. 1994;
1995), where the effect of acute nicotine challenge on extracellular concentration of
DA in the dorsal striatum and those of DA, DOPAC and HVA in NAcc was attenuated
during constant nicotine infusion. Furthermore, in contrast to saline-infused animals
acute nicotine treatment induced no changes in striatal DA metabolism in rats and
mice on the seventh day of continuous nicotine infusion. These phenomena could be
due to the continuous presence of an agonist, in this case nicotine, desensitizing the
nicotinic acetylcholine receptors (nAChRs) regulating the dopaminergic neurons. In
our studies, the attenuation of nicotine's effect on DA metabolism occurred with
prolonged exposure of rats and mice to nicotine concentrations similar to those found
in the plasma of heavy smokers (Table 5.1). Furthermore, such plasma concentrations
indicate high cerebral nicotine concentrations in rats and mice as noted in section 6.1.
Lippiello et al. (1995) observed that nicotine tends to stabilize nAChRs in the high
affinity conformation which is related to the process of functional desensitization
(Marks et al. 1983; see section 2.1.4). Thus, our experiments indicate that nAChRs
involved in the control of striatal and limbic dopamine metabolism and turnover were
desensitized during constant nicotine infusion.
According to the studies performed in mice, the desensitization of nAChRs regulating
DA metabolism seems to be dose-dependent. The results of Leikola-Pelho et al.
(1990), demonstrating that a 3 mg/kg acute dose of nicotine did not any more increase
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DOPAC and HVA as compared with smaller doses and even decreased them during
chronic nicotine, supports this suggestion.
In nicotine-infused rats we found differences in the levels of striatal and limbic DA
metabolites during chronic infusion as well as after acute nicotine administration
These results suggest that at least some of the limbic nAChRs mediating nicotine’s
effects on dopamine turnover are less easily desensitized than the striatal ones. This
finding agrees with the suggestion of Henningfield et al . (1996) based on in vitro
experiments (Brodie 1991; Grady et al. 1994; Rapier et al. 1988) that somatodendritic
nAChRs located on mesolimbic DA neurons appear to desensitize much less readily
than nAChRs located on the terminals of the nigrostriatal pathway. In vitro the subunit
composition of nAChRs determines the degree to which receptors are desensitized by
various concentrations of nicotine (Fenster et al. 1997), for example, the a4 subunit
has been found to be more sensitive to desensitization than a3. Dalack et al. (1998)
suggested that there may be more a3-subunit containing receptors in the NAcc than in
the dorsal striatum, based on functional studies of Brioni et al. (1995) and Mirza et al.
(1996) where nicotine agonists ABT-418 and isoarecolone were used. ABT-418 and
isoarecolone have much higher affinity for receptors containing a4-subunit than those
containing a3 (Papke et al. 1997). Treatment with ABT-418 is three times less potent
at activating ventral tegmental area neurons than nicotine (Brioni et al. 1995), while
isoarecolone is much less potent than nicotine at stimulating dopamine release in the
nucleus accumbens (Mirza et al. 1996).
6.3.2 The long-lasting inactivation of nAChRs regulating cerebral dopamine
metabolism in rats
After 24-h and 72-h withdrawal from nicotine infusion, acute nicotine elevated striatal
DOPAC and HVA to the same extent in nicotine-infused and saline-infused rats. The
loss of function of the nAChRs regulating striatal DA metabolism during chronic
nicotine infusion is thus a reversible phenomenon recovering, within 24-h of
withdrawal. Acute nicotine also elevated limbic HVA concentrations similarly in the
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control and in the nicotine-withdrawn rats. However, the nicotine-induced elevation of
limbic DOPAC was still abolished after 24-h withdrawal, but not after 72-h
withdrawal. Thus, nAChRs mediating nicotine-induced elevation of limbic DOPAC
were still inactivated after 24-h withdrawal when no nicotine and only traces of
cotinine were detected in the plasma. The lack of response of limbic DOPAC to acute
nicotine could be due to long-lasting inactivation of nAChR function which in in vitro
experiments has been distinguished from reversible receptor desensitization and which
is caused by the prolonged pretreatment or high concentrations of nicotine (Rowell and
Duggan 1998). These long-lived inactive receptor states are likely to underlie the
development of tolerance to nicotine (Fenster et al. 1999b).
We could not demonstrate any nicotine-induced sensitization in either striatal or limbic
DA metabolism either when nicotine was infused constantly or withdrawn for 24 or 72
hours. This agrees with previous findings when nicotine was given by constant
infusion (Benwell et al. 1995; Marshall et al. 1997). The effect of chronic nicotine
treatment seems to depend on the method of administration. Intermittent
administration protocols resulted in sensitization of the response (Balfour et al. 1998;
Cadoni and Di Chiara 2000; Nisell et al. 1996), whereas constant infusion produces
desensitization as found in this study (Benwell et al. 1995; Marshall et al. 1997).
6.4 Fos protein expression: brain areas activated by acute nicotine
administration
The primary Fos antibody used in this study was raised against amino acids 2-16 of the
N-terminal region of the cFos-protein, thus it indicates the activation of expression of
the c-fos gene only (Herrera and Robertson 1996; van Straaten et al. 1983).
In this study the basal levels of Fos expression in control rats, handled in a way similar
to the rats in acute and chronic nicotine experiments but given saline instead of
nicotine, were rather low. The prefrontal and cingulate cortices showed somewhat
more Fos IS than was found in control rats. Additionally, the excessive background
staining in these two brain areas somewhat interfered with the counting of the Fos-
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positive nuclei. Since the basal Fos expression was low (Tables 5.4 and 5.5) in the
stress-related areas PVN, SON and ACe (Senba and Ueyama 1997) we can assume
that the animals did not experience stress caused by experimental conditions.
Acute nicotine administration increased the number of Fos-positive nuclei in striatal
and limbic dopaminergic target areas, namely in the dorsomedial CPU, the core of
NAcc, Cg and in the ACe. Also, acute nicotine tended to increase the Fos expression
in the PFC (Table 5.5). In agreement with earlier experiments (Nisell et al. 1997) acute
nicotine at the dose of 0.5 mg/kg did not significantly increase Fos-expression in the
shell of the NAcc. The nicotine-induced increase in Fos protein expression in
dopaminergic target areas could indicate the postsynaptic effects of nicotine-induced
dopamine release in nigrostriatal and mesocorticolimbic dopaminergic systems. The
observation that the D1 receptor antagonist SCH23390 blocks nicotine-induced Fos
expression in striatum, NAcc and PFC, supports this suggestion (Kiba and Jayaraman
1994; Nisell et al. 1997).
Acute nicotine increased the number of Fos-positive nuclei in the SC and in the MT
which nuclei are known to be included in the visual system. These results agree with
earlier studies that have consistently described nicotine’s effect on the visual system
measuring either local cerebral glucose utilization (Grünwald et al. 1987; London et al.
1988) or Fos immunostaining (Mathieu-Kia et al. 1998; Pang et al. 1993; Ren and Sagar
1992). Furthermore, as shown earlier, acute nicotine increased Fos expression in the
hypothalamic PVN, SON and IPN, a nucleus connected to the midbrain limbic system
(see Sections 2.3.2 and 2.3.3).
6.5 The interaction of nicotine and diazepam in the induction of Fos expression
The findings that nicotine increases Fos expression in stress-related brain areas PVN,
SON and ACe led us to study the effects of diazepam on nicotine-induced Fos
expression. Diazepam in this case significantly activated Fos IS in the PVN, SON and
ACe. However, it did not increase Fos IS in the MT, IP and VLG areas. Diazepam,
when administered prior to nicotine, did not prevent nicotine-induced Fos expression in
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any brain area studied. Furthermore, we found no significant interactions between the
acute effects of diazepam and nicotine on Fos IS, although nicotine tended to antagonise
the diazepam-induced elevation of Fos IS in ACe.
In this study, the rather large doses of diazepam had significant effect on Fos expression
in stress-related brain areas. Niles and co-workers noticed that 5 mg/kg diazepam
increased Fos expression, as measured by Western blotting, in the striatum but not in
hippocampus (Niles et al. 1997). Fos protein induction is thought to reflect neuronal
activation and typically occurs in response to various convulsant agents (Niles et al.
1997). Thus, it is somewhat paradoxical that the anticonvulsant diazepam increased the
number of Fos-positive nuclei in various brain areas. Lack of interactions between
diazepam and nicotine in inducing the expression of Fos suggests that these drugs
activate different sets of neurons in these brain areas. In the pcPVN nicotine activates
neurons which are known to mediate ACTH release. In the SON nicotine activates both
vasopressinergic and oxytocinergic neurons (Matta et al. 1993). At present it is not clear
which subclasses of neurons diazepam activates in these brain areas. Further, previous
studies indicate no relationship between the density of benzodiazepine binding sites and
the extent to which diazepam decreased stress-induced c-fos expression (Beck and
Fibiger 1995). Balfour (1991) has earlier concluded that nicotine’s anxiolytic properties
are unlikely to be associated with GABAA receptors that are thought to mediate the
anxiolytic properties of the benzodiazepines. Certainly further experiments are needed to
clarify the effects of diazepam in the induction of Fos protein. As the diazepam dose
used was quite large, it would be interesting to study the dose-response especially at
smaller doses of diazepam.
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6.6 The effect of chronic nicotine treatment and its withdrawal on nicotine-
induced Fos protein expression
6.6.1 Dopaminergic target areas
Chronic nicotine treatment
The attenuation of nicotine-induced Fos IS in the CPU might be due to desensitization
as discussed in section 6.3.1 regarding striatal dopamine during the chronic nicotine
infusion. In contrast to the findings in the CPU, acute nicotine administration caused a
slight increase in the number of Fos-positive nuclei in the NAcc of rats during chronic
nicotine infusion and no decrease of nicotine-induced Fos IS was found in the limbic
areas, Cg and ACe. Furthermore, as discussed above, limbic HVA was somewhat
elevated by acute nicotine during chronic nicotine treatment. Thus, in the same way to
nicotine’s effects on limbic dopamine metabolism, its Fos expression increasing effect
in the limbic brain areas seems to be less easily attenuated during chronic nicotine
treatment than its effects in the CPU area. Thus, this could indicate that nAChRs
mediating nicotine's postsynaptic effects in the striatal areas might desensitize more
easily than the ones in the limbic areas. The observed differences in the striatal and
limbic areas between nicotine’s effects on both DA metabolites and Fos expression
suggest that nAChRs and their receptor states in these brain areas might differ. As
nAChR states vary according to subunit composition (Cachelin and Jaggi 1991; Hsu et
al. 1996) subtypes of nAChRs may be differentially involved in the acute and chronic
effects of nicotine and their associated cellular compensatory events (Balfour 1994).
Nicotine-withdrawal
Withdrawal itself (24 or 72 h) did not change Fos expression. After 24-h withdrawal
acute nicotine did not increase the Fos IS in the CPU, the NAcc or in the Cg. The
inability of nicotine to induce Fos-expression in the CPU and NAcc could be due to
the long-lasting inactivation of nAChRs as discussed in section 6.3.2. (Rowell and
Duggan, 1998). It should be noted that on the seventh day of treatment when there was
a marked amount of nicotine present, acute nicotine did not increase Fos IS in the CPU
and only increased Fos IS to a small degree in the NAcc. Further, the inability of
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nicotine to induce Fos expression in the NAcc seems to correlate with the finding that
acute nicotine did not elevate limbic DOPAC of rats withdrawn for 24 h. The inability
of acute nicotine to induce Fos expression in the CPU does not correlate with our
findings on DA metabolites. Dopaminergic pathways are not necessarily the only ones
involved in mediating nicotine’s effects on Fos-protein expression during withdrawal.
Cortical and thalamic glutamatergic inputs to the striatum may modulate the
dopaminergic activation of postsynaptic intracellular mechanisms leading to changes
in Fos expression (Harlan and Garcia, 1998). Acute nicotine’s effects on DA
metabolites were found to be similar to its effects on Fos expression in that both were
fully restored within 72 h after withdrawal of nicotine infusion.
6.6.2 The relationship of nicotine-induced changes between dopamine
metabolism and Fos protein expression in dopaminergic target areas
Interestingly, nicotine’s effects on Fos protein expression in dopaminergic target areas
seem to correlate with the changes in dopamine release and metabolism. In the present
study, the attenuation of both nicotine-induced dopamine metabolism and Fos protein
expression in the CPU area during constant nicotine infusion was demonstrated in rats,
when there were marked nicotine and cotinine concentrations present in the plasma.
Furthermore, evidence for a long-lasting inactivation of nAChRs mediating nicotine’s
effects on limbic dopamine metabolism and on Fos-expression in striatal and limbic
areas was found during the 24-h withdrawal, when there was no nicotine and only
traces of cotinine in plasma of these rats. Nisell and coauthors observed the
sensitization of both dopamine release in vivo and Fos protein expression in the PFC
after intermittent nicotine administration for 12 days in rats (Nisell et al. 1996; 1997).
In the NAcc, no sensitization of either response was observed (Nisell et al. 1996;
1997). It seems that at least, in the case of brain dopaminergic systems, the functional
status of nAChRs involved in nicotine’s effects correlates well with the level of c-fos.
Thus, Fos expression could not only map the location of activity but could also
indicate the pattern of postsynaptic stimulation in these neuronal pathways.
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6.6.3 Other brain areas
The effects of 7-day chronic nicotine infusion and 72-h withdrawal on the nicotine-
induced increase in Fos expression were also studied in the PVN, SON and IPN. Fos
protein expression in response to acute nicotine was abolished in the PVN and SON on
the 7th day of nicotine infusion. This phenomenon could be caused by desensitization
of nAChRs located in these hypothalamic areas or in the regions regulating the
functions of these areas. After 72-h withdrawal, nicotine’s effects on Fos protein
expression were restored showing that the desensitization of nAChRs is a transient and
reversible phenomenon.
The increase of c-fos mRNA levels has been found to be desensitized in several brain
areas, including the PVN, when two intermittent nicotine injections (i.p.) were given at
2-h intervals (Sharp et al. 1993a). Sharp and Beyer (1986) demonstrated that by
repeating nicotine administration, nicotine-induced release of ACTH was almost
totally abolished. Also, nicotine-induced NA release in the PVN was found to be
reduced by 50 - 60% when two nicotine injections were given at 100 min intervals
either i.p. or directly into the fourth ventricle (Matta et al. 1995; Sharp and Matta
1993). All these effects were concluded to result from desensitization of nAChRs. Our
results show that the nAChRs mediating the effects of nicotine in the PVN or SON
seem to be desensitized or tolerant during chronic nicotine infusion as estimated by the
Fos protein expression. This method does not reveal the actual location of the nAChRs
that were desensitized; whether it occurs in NA-releasing neurons originating from the
brainstem or within the PVN is unknown. Both a4 and even more likely a7 subunit
containing nAChRs, which are now suggested to mediate nicotine’s effects in the SON
(Zaninetti et al. 2000), are reported to desensitize during nicotine exposure (Fenster et
al. 1997).
The attenuation of Fos IS in the IPN was clear but not as pronounced as in the PVN
and SON, because acute nicotine still significantly increased the Fos IS during chronic
nicotine infusion. This correlates quite well with our observations that in rats infused
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chronically with nicotine, acute nicotine still, to some degree, increased the Fos IS in
the NAcc and furthermore, no decrease of nicotine-induced Fos IS was found in the
Cg and ACe of these rats indicating that limbic nAChRs do not readily desensitize
during chronic nicotine treatment.
These findings suggest that the levels of desensitization of nAChRs in various brain
areas differ. The nAChRs in the hypothalamic areas, PVN and SON, or in their input
areas regulating nicotine’s effects on hormone secretion seem to be desensitized more
easily than the nAChRs in the limbic areas controlling behaviour such as in the IPN.
Thus, there seems to be variations in the functional states and/or in the subunit
combinations of nAChRs mediating nicotine’s effects in brain.
6.7 The development of tolerance in nicotine-infused mice
The hypothermic effect of nicotine is mediated by central nAChRs (Mansner et al.
1974) and can be prevented by elevating the ambient temperature (Haikala et al.
1986). In several studies chronic nicotine treatment was found to induce tolerance to
the nicotine-induced decrease of body temperature (Mansner et al. 1974; Marks and
Collins 1985). Further, in mice withdrawn for 24 h from a seven-week oral nicotine
administration schedule (Pietilä et al. 1996), acute nicotine challenge induced
significantly less hypothermia than in controls indicating the development of tolerance
to the hypothermic effect of nicotine. Tolerance also developed to the locomotor-
depressant effects of acute nicotine in these mice (Pietilä et al. 1998). In Study IV,
acute nicotine doses of 1 and 2 mg/kg induced hypothermia in a dose-dependent
manner which was at its maximum at 30 min after administration of the drug. In mice
infused chronically with nicotine from subcutaneously implanted nicotine-releasing
reservoirs for 7 days, tolerance was found to the hypothermic effect of the acute
nicotine dose of 1 mg/kg but not to the dose of 2 mg/kg. Previously no tolerance was
observed to the hypothermic effect of large or repeated (3 mg/kg or 1 x 4 mg/kg s.c.)
acute nicotine doses after 7-day chronic nicotine infusion in mice (Leikola-Pelho et al.
1990). Thus, we found that increasing the nicotine dose overcomes the attenuation of
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the hypothermic effect of nicotine. This suggests that tolerance, in the classical sense,
i.e. an effect that is characterised by the fact that increasing the dose of the drug
overcomes the diminution of its effect following repeated administration, develops to
nicotine-hypothermia during chronic treatment. In contrast, during chronic nicotine
treatment, acute nicotine did not increase the concentrations of striatal DA metabolites
suggesting that desensitization is the main mechanism by which the nAChRs
regulating striatal DA metabolism, are inactivated under the present experimental
conditions. Thus, the nAChRs involved in these two effects differ.
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7 SUMMARY AND CONCLUSIONS
In the present study both desensitization and long-lasting inactivation of the nAChRs
involved in the mediation of nicotine’s central effects on cerebral dopamine
metabolism and on Fos expression were demonstrated in vivo in rodent brain during
chronic nicotine administration and its withdrawal.
1) In rat acute administration of nicotine induced Fos IS both in the CPU and limbic
dopaminergic areas. Acutely administered nicotine also induced Fos IS in both the PVN
and SON, which are stress-related brain areas, and in MT and IPN. Diazepam induced
Fos IS in all stress-related areas studied (PVN, SON, ACe), but not in any of the other
brain areas studied. No significant interactions were found between the acute effects of
diazepam and nicotine on Fos expression and this finding suggests that these drugs
activate different sets of neurons within the stress-related brain areas.
2) The results from studies performed in the rat suggest that the degree of
desensitization of nAChRs in various brain areas differs. The nAChRs in the striatal
areas seem to be desensitized more easily than those in the limbic areas during
prolonged nicotine infusion. Thus, in the CPU area neither the elevation of DA
metabolites nor the expression of Fos protein was affected by acute nicotine during
chronic nicotine infusion. In contrast, acute nicotine administration caused some
elevation of both limbic HVA and Fos expression in the NAcc of rats during chronic
nicotine infusion. No reduction of nicotine-induced Fos expression was found in the
Cg and ACe, and only a slight reduction was found in the IPN which are known to be
brain areas involved in regulation of various behavioural reactions. Further, the
nAChRs in the hypothalamic areas, PVN and SON, or in their input areas regulating
nicotine’s effects on hormone secretion also seem to be more easily desensitized than
the nAChRs in the limbic areas.
We also found evidence for a long-lasting inactivation of nAChRs mediating
nicotine’s effects in vivo. Thus, at 24 h after withdrawal acute nicotine did not elevate
limbic DOPAC, but striatal DOPAC and HVA as well as limbic HVA were elevated to
the same degree as in control rats. Furthermore, acute nicotine did not increase the Fos
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expression in the CPU or NAcc, although in ACe its effects were similar to that in
controls.
After longer withdrawal (72 h) nicotine’s effects on cerebral dopamine metabolism
and Fos protein expression were restored showing that these functional changes of
nAChRs are reversible phenomena.
3) In mice, the responses of striatal DA metabolism and body temperature to acute
nicotine were both reduced during constant nicotine infusion. However, the tolerance
to nicotine’s hypothermic effect could be overcome to some degree by increasing the
dose of nicotine, suggesting that tolerance, in the classical sense, develops in nAChRs
involved in thermoregulation during chronic nicotine treatment. In contrast, during
chronic nicotine treatment acute nicotine did not increase the concentrations of striatal
DA metabolites suggesting that desensitization is the main mechanism by which
nAChRs regulating striatal DA metabolism are inactivated under the present
experimental conditions. Thus, the nAChRs involved in these two effects differ.
In conclusion, there seems to be variations in the functional states and/or in the subunit
combinations of nAChRs mediating nicotine’s effects in brain. It has been
hypothesized that smokers, seeking the most rewarding effect, adjust their way of
smoking so that they reach the appropriate combination of stimulated and desensitized
nAChRs. The long-lasting inactivation of nAChRs is one of the important factors in
the development of tolerance to nicotine. The variations in responses to nicotine may
prove to be useful when studying the protective effect of nicotine in Parkinson’s
disease as well as in its reinforcing and dependence-producing properties.
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